<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">96812</article-id>
<article-id pub-id-type="doi">10.7554/eLife.96812</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.96812.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.1</article-version>
</article-version-alternatives>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology and Inflammation</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neurotrophic factor Neuritin modulates T cell electrical and metabolic state for the balance of tolerance and immunity</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name>
<surname>Yu</surname>
<given-names>Hong</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
<xref ref-type="author-notes" rid="n1">#</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Nishio</surname>
<given-names>Hiroshi</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="author-notes" rid="n1">#</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Barbi</surname>
<given-names>Joseph</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="author-notes" rid="n1">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mitchell-Flack</surname>
<given-names>Marisa</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vignali</surname>
<given-names>Paolo D. A.</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zheng</surname>
<given-names>Ying</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lebid</surname>
<given-names>Andriana</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chang</surname>
<given-names>Kwang-Yu</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fu</surname>
<given-names>Juan</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Higgins</surname>
<given-names>Makenzie</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Ching-Tai</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Xuehong</given-names>
</name>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Zhiguang</given-names>
</name>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Blosser</surname>
<given-names>Lee</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tam</surname>
<given-names>Ada</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9610-3677</contrib-id>
<name>
<surname>Drake</surname>
<given-names>Charles G.</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pardoll</surname>
<given-names>Drew M.</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Bloomberg-Kimmel Institute for Cancer Immunotherapy, Immunology and Hematopoiesis Division, Department of Oncology, Johns Hopkins University School of Medicine</institution>, Baltimore, Maryland</aff>
<aff id="a2"><label>2</label><institution>The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine</institution>, Baltimore, Maryland</aff>
<aff id="a3"><label>3</label><institution>Department of Obstetrics and Gynecology, Keio University School of Medicine</institution>, Tokyo 160-8582, <country>Japan</country></aff>
<aff id="a4"><label>4</label><institution>Department of Immunology, Roswell Park Comprehensive Cancer Center</institution>, Buffalo, NY14263, <country>USA</country></aff>
<aff id="a5"><label>5</label><institution>University of Pittsburgh</institution>, Carnegie Mellon</aff>
<aff id="a6"><label>6</label><institution>National Institute of Cancer Research, National Health Research Institutes</institution>, Tainan, <country>Taiwan</country></aff>
<aff id="a7"><label>7</label><institution>Infectious Diseases, Department of Medicine, Chang Gung Memorial Hospital</institution>, <country>Taiwan</country></aff>
<aff id="a8"><label>8</label><institution>Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University</institution>, Dalian 116044, <country>China</country></aff>
<aff id="a9"><label>9</label><institution>Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center</institution>, New York, New York 10032</aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Sakaguchi</surname>
<given-names>Shimon</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Osaka University</institution>
</institution-wrap>
<city>Osaka</city>
<country>Japan</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Taniguchi</surname>
<given-names>Tadatsugu</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>University of Tokyo</institution>
</institution-wrap>
<city>Tokyo</city>
<country>Japan</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>Correspondence to <email>hyu13@jhmi.edu</email>.</corresp>
<fn id="n1" fn-type="equal"><label>#</label><p>These authors contributed equally to this work.</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2024-06-12">
<day>12</day>
<month>06</month>
<year>2024</year>
</pub-date>
<volume>13</volume>
<elocation-id>RP96812</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2024-03-10">
<day>10</day>
<month>03</month>
<year>2024</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2024-02-02">
<day>02</day>
<month>02</month>
<year>2024</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.01.31.578284"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2024, Yu et al</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Yu et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-96812-v1.pdf"/>
<abstract>
<title>Abstract</title>
<p>The adaptive T cell response is accompanied by continuous rewiring of the T cell’s electric and metabolic state. Ion channels and nutrient transporters integrate bioelectric and biochemical signals from the environment, setting cellular electric and metabolic states. Divergent electric and metabolic states contribute to T cell immunity or tolerance. Here, we report that neuritin (Nrn1) contributes to tolerance development by modulating regulatory and effector T cell function. Nrn1 expression in regulatory T cells promotes its expansion and suppression function, while expression in the T effector cell dampens its inflammatory response. Nrn1 deficiency causes dysregulation of ion channel and nutrient transporter expression in Treg and effector T cells, resulting in divergent metabolic outcomes and impacting autoimmune disease progression and recovery. These findings identify a novel immune function of the neurotrophic factor Nrn1 in regulating the T cell metabolic state in a cell context-dependent manner and modulating the outcome of an immune response.</p>
</abstract>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>CD is a co-inventor on patents licensed from JHU to BMS and Janssen and is currently an employee of Janssen Research. DMP is a consultant for Compugen, Shattuck Labs, WindMIL, Tempest, Immunai, Bristol-Myers Squibb, Amgen, Janssen, Astellas, Rockspring Capital, Immunomic, and Dracen, owns founders equity in ManaT Bio Inc., WindMIL, Trex, Jounce, Enara, Tizona, Tieza, and RAPT; and receives research funding from Compugen, Bristol-Myers Squibb, and Enara. None of the other authors have conflicting financial interests.</p></notes>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Peripheral T cell tolerance is important in restricting autoimmunity and minimizing collateral damage during active immune reactions and is achieved via diverse mechanisms, including T cell anergy, regulatory T (Treg) cell mediated suppression, and effector T (Te) cell exhaustion or deletion (<xref ref-type="bibr" rid="c19">ElTanbouly and Noelle, 2021</xref>). Upon activation, Treg and conventional T cells integrate environmental cues and adapt their metabolism to the energetic and biosynthetic demands, leading to tolerance or immunity. Tolerized versus responsive T cells are characterized by differential metabolic states. For example, T cell anergy is associated with reduced glycolysis, whereas activated T effector cells exhibit increased glycolysis (<xref ref-type="bibr" rid="c9">Buck et al., 2017</xref>; <xref ref-type="bibr" rid="c24">Geltink et al., 2018</xref>; <xref ref-type="bibr" rid="c53">Peng and Li, 2023</xref>; <xref ref-type="bibr" rid="c82">Zheng et al., 2009</xref>). Cellular metabolic states depend on electrolyte and nutrient uptake from the microenvironment (<xref ref-type="bibr" rid="c11">Chapman and Chi, 2022</xref>; <xref ref-type="bibr" rid="c50">Olenchock et al., 2017</xref>). Ion channels and nutrient transporters, which can integrate environmental nutrient changes, affect the cellular metabolic choices and impact the T cell functional outcome (<xref ref-type="bibr" rid="c4">Babst, 2020</xref>; <xref ref-type="bibr" rid="c6">Bohmwald et al., 2021</xref>; <xref ref-type="bibr" rid="c56">Ramirez et al., 2018</xref>). Each cell’s functional state would correspond with a set of ion channels and nutrient transporters supporting their underlying metabolic requirements. The mechanisms coordinating the ion channel and nutrient transporter expression changes to support the adaptive T cell functional state in the immune response microenvironment remain unclear.</p>
<p>Nrn1, also known as candidate plasticity gene 15 (CPG15), was initially discovered as a neurotrophic factor linked to the neuronal cell membrane through a glycosylphosphatidylinositol (GPI) anchor (<xref ref-type="bibr" rid="c47">Nedivi et al., 1998</xref>; <xref ref-type="bibr" rid="c84">Zhou and Zhou, 2014</xref>). It is highly conserved across species, with 98% overall homology between the murine and human protein. Nrn1 plays multiple roles in neural development, synaptic plasticity, synaptic maturation, neuronal migration, and survival (<xref ref-type="bibr" rid="c10">Cantallops et al., 2000</xref>; <xref ref-type="bibr" rid="c29">Javaherian and Cline, 2005</xref>; <xref ref-type="bibr" rid="c47">Nedivi et al., 1998</xref>; <xref ref-type="bibr" rid="c55">Putz et al., 2005</xref>; <xref ref-type="bibr" rid="c86">Zito et al., 2014</xref>). In the immune system, Nrn1 expression has been found in Foxp3<sup>+</sup> Treg and follicular regulatory T cells (Tfr) (<xref ref-type="bibr" rid="c25">Gonzalez-Figueroa et al., 2021</xref>; <xref ref-type="bibr" rid="c74">Vahl et al., 2014</xref>), T cells from transplant tolerant recipients (<xref ref-type="bibr" rid="c37">Lim et al., 2013</xref>), anergized CD8 cells or CD8 cells from tumor-infiltrating lymphocytes in mouse tumor models (<xref ref-type="bibr" rid="c61">Schietinger et al., 2012</xref>; <xref ref-type="bibr" rid="c62">Schietinger et al., 2016</xref>; <xref ref-type="bibr" rid="c69">Singer et al., 2016</xref>), and in human Treg infiltrating breast cancer tumor tissue (<xref ref-type="bibr" rid="c54">Plitas et al., 2016</xref>). Soluble Nrn1 can be released from Tfr cells and act directly on B cells to suppress autoantibody development against tissue-specific antigens (<xref ref-type="bibr" rid="c25">Gonzalez-Figueroa et al., 2021</xref>). Despite the observation of Nrn1 expression in Treg cells and T cells from tolerant environments (<xref ref-type="bibr" rid="c25">Gonzalez-Figueroa et al., 2021</xref>; <xref ref-type="bibr" rid="c37">Lim et al., 2013</xref>; <xref ref-type="bibr" rid="c54">Plitas et al., 2016</xref>; <xref ref-type="bibr" rid="c61">Schietinger et al., 2012</xref>; <xref ref-type="bibr" rid="c62">Schietinger et al., 2016</xref>; <xref ref-type="bibr" rid="c69">Singer et al., 2016</xref>), the roles of Nrn1 in T cell tolerance development and Treg cell function have not been explored, and functional mechanism of Nrn1 remains elusive. This study demonstrates that the neurotrophic factor Nrn1 can moderate T cell tolerance and immunity through both Treg and Te cells, impacting Treg cell expansion and suppression while controlling inflammatory response in Te cells.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Nrn1 expression and function in T cell anergy</title>
<p>To explore the molecular mechanisms underlying peripheral tolerance development, we utilized a system we previously developed to identify tolerance-associated genes (<xref ref-type="bibr" rid="c28">Huang et al., 2004</xref>). We compared the gene expression patterns associated with either a T effector/memory response or tolerance induction triggered by the same antigen but under divergent <italic>in vivo</italic> conditions (<xref ref-type="bibr" rid="c28">Huang et al., 2004</xref>). Influenza hemagglutinin (HA) antigen-specific TCR transgenic CD4 T cells were adoptively transferred into WT recipients with subsequent HA-Vaccinia virus (VacHA) infection to generate T effector/memory cells while tolerogenic HA-specific CD4s were generated by transfer into hosts with transgenic expression of HA as self-antigen (C3-HA mice, <xref rid="fig1" ref-type="fig">Figure 1A</xref>.)(<xref ref-type="bibr" rid="c28">Huang et al., 2004</xref>). One of the most differentially expressed genes upregulated in the anergy-inducing condition was Nrn1. Nrn1 expression was significantly higher among cells recovered from C3-HA hosts vs. cells from VacHA infected mice at all time points tested by qRT-PCR (<xref rid="fig1" ref-type="fig">Figure 1A</xref>). To further confirm the association of Nrn1 expression with T cell anergy, we assessed Nrn1 expression in naturally occurring anergic polyclonal CD4<sup>+</sup> T cells (Ta), which can be identified by surface co-expression of Folate Receptor 4 (FR4) and the ecto-5’-nucleotidase CD73 (Ta, CD4<sup>+</sup>CD44<sup>+</sup>FR4<sup>hi</sup>CD73<sup>hi</sup> cells)(<xref ref-type="bibr" rid="c31">Kalekar et al., 2016</xref>). Nrn1 expression was significantly higher in Ta than in naïve CD4 (Tn, CD4<sup>+</sup>CD62L<sup>+</sup>CD44<sup>-</sup>FR4<sup>-</sup>CD73<sup>-</sup>) and antigen-experienced cells (Te, CD4<sup>+</sup>CD44<sup>+</sup>FR4<sup>-</sup>CD73<sup>-</sup>) under steady-state conditions measured by both qRT-PCR and western blot (<xref rid="fig1" ref-type="fig">Figure 1B</xref>). Given that Treg cells, like anergic cells, have roles in maintaining immune tolerance, we queried whether Nrn1 is also expressed in Treg cells. Nrn1 expression can be detected in nTreg and induced Treg (iTreg) cells generated <italic>in vitro</italic> (<xref rid="fig1" ref-type="fig">Figure 1C</xref>). To evaluate Nrn1 expression under pathological tolerant conditions (<xref ref-type="bibr" rid="c15">Cuenca et al., 2003</xref>), we evaluated Nrn1 expression in T cells within the tumor microenvironment. Nrn1 expression in murine Treg cells and non-Treg CD4<sup>+</sup> cells from tumor infiltrates were compared to the Treg cells and non-Treg CD4<sup>+</sup> T cells isolated from peripheral blood. Nrn1 mRNA level was significantly increased among tumor-associated Treg cells and non-Treg CD4 cells compared to cells from peripheral blood (Figure 1-figure supplement 1A). Consistent with our findings in the mouse tumor setting, the Treg and non-Treg T cells from human breast cancer infiltrates reveal significantly higher Nrn1 expression compared to the peripheral blood Treg and non-Treg cells (Figure 1-figure supplement 1B) (<xref ref-type="bibr" rid="c54">Plitas et al., 2016</xref>).</p>
<p>CD4<sup>+</sup> T cells may pass through an effector stage after activation before reaching an anergic state (<xref ref-type="bibr" rid="c2">Adler et al., 1998</xref>; <xref ref-type="bibr" rid="c13">Chen et al., 2004</xref>; <xref ref-type="bibr" rid="c27">Huang et al., 2003</xref>; <xref ref-type="bibr" rid="c51">Opejin et al., 2020</xref>). To evaluate the potential role of Nrn1 expression in T cell tolerance development, we further examined Nrn1 expression kinetics after T cell activation. Nrn1 expression was significantly induced after CD4<sup>+</sup> T cell activation (<xref rid="fig1" ref-type="fig">Figure 1D</xref>). Using a Nrn1 specific antibody, Nrn1 can be detected on activated CD4<sup>+</sup> and CD8<sup>+</sup> cells (<xref rid="fig1" ref-type="fig">Figure 1D</xref>, Figure 1-figure supplement 1C). The significant enhancement of Nrn1 expression after T cell activation suggests that Nrn1 may contribute to the process of T cell tolerance development and/or maintenance.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Nrn1 expression and function in anergic T cells.</title>
<p>(<bold>A</bold>) Experimental scheme identifying Nrn1 in anergic T cells and qRT-PCR confirmation of Nrn1 expression in HA-specific CD4 cells recovered from HA-expressing host vs WT host activated with Vac_HA virus. (<bold>B</bold>) qRT-PCR and western blot detecting Nrn1 expression in naïve CD4<sup>+</sup>CD62L<sup>hi</sup>CD44<sup>lo</sup> Tn cell, CD4<sup>+</sup>Foxp3<sup>-</sup>CD44<sup>hi</sup>CD73<sup>-</sup>FR<sup>-</sup> Te cells and CD4<sup>+</sup>Foxp3<sup>-</sup> CD44<sup>hi</sup>CD73<sup>+</sup>FR<sup>+</sup> Ta cells. (<bold>C</bold>) Nrn1 expression was measured by qRT-PCR and western blot among naïve CD4<sup>+</sup> T cells, CD4<sup>+</sup>Foxp3<sup>+</sup> nTreg, and <italic>in vitro</italic> generated iTregs. (<bold>D</bold>) Nrn1 expression was detected by qRT-PCR and flow cytometry among naïve CD4<sup>+</sup> cells and activated CD4<sup>+</sup> cells on days 1, 2, and 3 after activation. qPCR Data are presented as average <underline>+</underline> SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001. Triplicates were used. Ordinary one-way ANOVA was performed for multi-comparison.</p><p>(<bold>E-J</bold>). Anergy induction <italic>in vivo</italic>. (<bold>E</bold>) Experimental outline evaluating anergy development <italic>in vivo</italic>: 2x10<sup>6</sup> Thy1.1<sup>+</sup> Nrn1<sup>-/-</sup> or ctrl CD4 OTII T cells were co-transferred with 5x10<sup>5</sup> Thy1.2<sup>+</sup>Thy1.1<sup>-</sup> WT Treg cells into TCRα<sup>-/-</sup>mice. Cells were recovered on day 13 post-transfer. (<bold>F</bold>) Proportions and numbers of OTII cells recovered from recipient spleen; (<bold>G</bold>) IL2 secretion from OTII cells upon <italic>ex vivo</italic> stimulation with OVA peptide. (<bold>H</bold>) Foxp3<sup>+</sup> cell proportion among Thy1.1<sup>+</sup> Nrn1<sup>-/-</sup> or ctrl CD4 cells. (<bold>I &amp; J</bold>) Nrn1<sup>-/-</sup> vs ctrl OTII cells recovered from the peptide-induced anergy model were subjected to bulk RNASeq analysis. GSEA comparing the expression of signature genes for anergy (<bold>I</bold>) and Treg (<bold>J</bold>) among ctrl and Nrn1<sup>-/-</sup> OTII cells.</p><p>Data are presented as mean <underline>+</underline>SEM and representative of 3 independent experiments (N<underline>&gt;</underline>4 mice per group). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. Unpaired Student’s t-tests were performed.</p></caption>
<graphic xlink:href="578284v1_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>To understand the functional implication of Nrn1 expression in immune tolerance, we analyzed Nrn1-deficient (Nrn1<sup>-/-</sup>) mice (<xref ref-type="bibr" rid="c23">Fujino et al., 2011</xref>). In the first evaluation of the Nrn1<sup>-/-</sup> colony, Nrn1<sup>-/-</sup> mice had consistently reduced body weight compared to heterozygous Nrn1<sup>+/-</sup> and WT (Nrn1<sup>+/+</sup>) mice (Figure 1-figure supplement 2A). The lymphoid tissues of Nrn1<sup>-/-</sup> mice were comparable to their Nrn1<sup>+/-</sup> and WT counterparts except for a slight reduction in cell number that was observed in the spleens of Nrn1<sup>-/-</sup> mice, likely due to their smaller size (Figure 1-figure supplement 2B). Analysis of thymocytes revealed no defect in T cell development (Figure 1-figure supplement 2C), and a flow cytometric survey of the major immune cell populations in the peripheral lymphoid tissue of these mice revealed similar proportions of CD4, CD8 T cells, B cells, monocytes and dendritic cells (DCs) (Figure 1-figure supplement 2D). Similarly, no differences were found between the proportions of anergic and Treg cells in Nrn1<sup>-/-</sup>, Nrn1<sup>+/-</sup> and WT mice (Figure 1-figure supplement 2E, F), suggesting that Nrn1 deficiency does not significantly affect anergic and Treg cell balance under steady state. Additionally, histopathology assessment of lung, heart, liver, kidney, intestine and spleen harvested from 13 months old Nrn1<sup>-/-</sup> and Nrn1<sup>+/-</sup> littermates did not reveal any evidence of autoimmunity (data not shown). The comparable level of anergic and Treg cell population among Nrn1<sup>-/-</sup>, Nrn1<sup>+/-</sup> and WT mice and lack of autoimmunity in Nrn1<sup>-/-</sup> aged mice suggest that Nrn1 deficiency is not associated with baseline immune abnormalities or overt dysfunction. Due to the similarity between Nrn1<sup>+/-</sup> and WT mice, we have used either Nrn1<sup>+/-</sup> or WT mice as our control depending on mice availability and referred to both as “ctrl” in the subsequent discussion.</p>
<p>To evaluate the relevance of Nrn1 in CD4<sup>+</sup> T cell tolerance development, we employed the classic peptide-induced T cell anergy model (<xref ref-type="bibr" rid="c75">Vanasek et al., 2006</xref>). Specifically, we crossed OVA antigen-specific TCR transgenic OTII mice onto the Nrn1<sup>-/-</sup> background. Nrn1<sup>-/-</sup>_OTII<sup>+</sup> or control_OTII<sup>+</sup> (ctrl_OTII<sup>+</sup>) cells marked with Thy1.1<sup>+</sup> congenic marker (Thy1.1<sup>+</sup>Thy1.2<sup>-</sup>), were co-transferred with polyclonal WT Tregs (marked as Thy1.1<sup>-</sup>thy1.2<sup>+</sup>), into TCRα knockout mice (TCRα<sup>-/-</sup>), followed by injection of soluble OVA peptide to induce clonal anergy (<xref rid="fig1" ref-type="fig">Figure 1E</xref>) (<xref ref-type="bibr" rid="c12">Chappert and Schwartz, 2010</xref>; <xref ref-type="bibr" rid="c42">Martinez et al., 2012</xref>; <xref ref-type="bibr" rid="c44">Mercadante and Lorenz, 2016</xref>; <xref ref-type="bibr" rid="c66">Shin et al., 2014</xref>). On day 13 after cell transfer, the proportion and number of OTII cells increased in the Nrn1<sup>-/-</sup>_OTII compared to the ctrl_OTII hosts (<xref rid="fig1" ref-type="fig">Figure 1F</xref>). Moreover, Nrn1<sup>-/-</sup>_OTII cells produced increased IL2 than ctrl_OTII upon restimulation (<xref rid="fig1" ref-type="fig">Figure 1G</xref>). Anergic CD4 Tconv cells can transdifferentiate into Foxp3<sup>+</sup> pTreg cells <italic>in vivo</italic> (DL, 2017; <xref ref-type="bibr" rid="c31">Kalekar et al., 2016</xref>; <xref ref-type="bibr" rid="c34">Kuczma et al., 2021</xref>). Consistent with reduced anergy induction, the proportion of Foxp3<sup>+</sup> pTreg among Nrn1<sup>-/-</sup>_OTII was significantly reduced (<xref rid="fig1" ref-type="fig">Figure 1H</xref>). In parallel with the phenotypic analysis, we compared gene expression between Nrn1<sup>-/-</sup>_OTII and ctrl_OTII cells by RNA Sequencing (RNASeq). Gene set enrichment analysis (GSEA) revealed that the gene set on T cell anergy was enriched in ctrl relative to Nrn1<sup>-/-</sup>_OTII cells (<xref rid="fig1" ref-type="fig">Figure 1I</xref>)(<xref ref-type="bibr" rid="c57">Safford et al., 2005</xref>). Also, consistent with the decreased transdifferentiation to Foxp3<sup>+</sup> cells, the Treg signature gene set was prominently reduced in Nrn1<sup>-/-</sup>_OTII cells relative to the ctrl (<xref rid="fig1" ref-type="fig">Figure 1J</xref>). Anergic T cells are characterized by inhibition of proliferation and compromised effector cytokines such as IL2 production (<xref ref-type="bibr" rid="c14">Choi and Schwartz, 2007</xref>). The increased cell expansion and cytokine production in Nrn1<sup>-/-</sup>_OTII cells and the reduced expression of anergic and Treg signature genes all support the notion that Nrn1 is involved in T cell anergy development.</p>
<p>Anergic T cells are developed after encountering antigen, passing through a brief effector stage, and reaching an anergic state (<xref ref-type="bibr" rid="c12">Chappert and Schwartz, 2010</xref>; <xref ref-type="bibr" rid="c27">Huang et al., 2003</xref>; <xref ref-type="bibr" rid="c67">Silva Morales and Mueller, 2018</xref>; <xref ref-type="bibr" rid="c81">Zha et al., 2006</xref>). Enhanced T cell activation, defective Treg cell conversion or expansion, and heightened T effector cell response may all contribute to defects in T cell anergy induction and/or maintenance (<xref ref-type="bibr" rid="c12">Chappert and Schwartz, 2010</xref>; <xref ref-type="bibr" rid="c27">Huang et al., 2003</xref>; <xref ref-type="bibr" rid="c31">Kalekar et al., 2016</xref>; <xref ref-type="bibr" rid="c67">Silva Morales and Mueller, 2018</xref>; <xref ref-type="bibr" rid="c81">Zha et al., 2006</xref>). We first examined early T cell activation to understand the underlying cause of defective anergy development in Nrn1<sup>-/-</sup> cells. Nrn1<sup>-/-</sup> CD4<sup>+</sup> cells showed reduced T cell activation, as evidenced by reduced CellTrace violet dye (CTV) dilution, activation marker expression, and Ca<sup>++</sup> entry after TCR stimulation (Figure 1-figure supplement 3A, B, C). The reduced early T cell activation observed in Nrn1<sup>-/-</sup> CD4 cells suggests that the compromised anergy development in Nrn1<sup>-/-</sup>_OTII cells was not caused by enhanced early T cell activation. The defective pTreg generation and/or enhanced effector T cell response may contribute to compromised anergy development.</p>
</sec>
<sec id="s2b">
<title>Compromised Treg expansion and suppression in the absence of Nrn1</title>
<p>The significant reduction of Foxp3<sup>+</sup> pTreg among Nrn1<sup>-/-</sup>_OTII cells could be caused by the diminished conversion of Foxp3<sup>-</sup> Tconv cells to pTreg and/or diminished Treg cell expansion and persistence. To understand the cause of pTreg reduction in Nrn1<sup>-/-</sup>_OTII cells (<xref rid="fig1" ref-type="fig">Figure 1H</xref>), we turned to the induced Treg (iTreg) differentiation system to evaluate the capability of Foxp3<sup>+</sup> Treg development and expansion in Nrn1<sup>-/-</sup> cells. Similar proportions of Foxp3<sup>+</sup> cells were observed in Nrn1<sup>-/-</sup> and ctrl cells under the iTreg culture condition, suggesting that Nrn1 deficiency does not significantly impact Foxp3<sup>+</sup> cell differentiation. To examine the capacity of iTreg expansion, Nrn1<sup>-/-</sup> and ctrl iTreg cells were restimulated with anti-CD3, and we found reduced live cells over time in Nrn1<sup>-/-</sup> iTreg compared to the ctrl (<xref rid="fig2" ref-type="fig">Figure 2A</xref>). The reduced live cell number in Nrn1<sup>-/-</sup> was accompanied by reduced Ki67 expression (<xref rid="fig2" ref-type="fig">Figure 2B</xref>). Although Nrn1<sup>-/-</sup> iTregs retained a higher proportion of Foxp3<sup>+</sup> cells three days after restimulation, however, when taking into account the total number of live cells, the actual number of live Foxp3<sup>+</sup> cells was reduced in Nrn1<sup>-/-</sup> (<xref rid="fig2" ref-type="fig">Figure 2C</xref>). Treg cells are not stable and are prone to losing Foxp3 expression after extended proliferation (<xref ref-type="bibr" rid="c21">Feng et al., 2014</xref>; <xref ref-type="bibr" rid="c22">Floess et al., 2007</xref>; <xref ref-type="bibr" rid="c36">Li et al., 2014</xref>; <xref ref-type="bibr" rid="c83">Zheng et al., 2010</xref>). The increased proportion of Foxp3<sup>+</sup> cells was consistent with reduced proliferation observed in Nrn1<sup>-/-</sup> cells. Thus, Nrn1 deficiency can lead to reduced iTreg cell proliferation and persistence <italic>in vitro</italic>.</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Reduced proliferation and suppression function in Nrn1<sup>-/-</sup> Treg cells.</title>
<p>(<bold>A-C</bold>) iTreg cell expansion after restimulation. (<bold>A</bold>) The number of live cells from day 1 to day 3 after iTreg cell restimulation with anti-CD3. (<bold>B</bold>) Ki67 expression among CD4<sup>+</sup>Foxp3<sup>+</sup> cells day 3 after restimulation. (<bold>C</bold>) Foxp3<sup>+</sup> cell proportion and number among live CD4<sup>+</sup> cells day 3 after restimulation. Triplicates in each experiment, data represent one of four independent experiments. (<bold>D-L</bold>). Nrn1<sup>-/-</sup> or ctrl nTreg cells expansion and suppression <italic>in vivo</italic>. (<bold>D</bold>) The experimental scheme. CD45.2<sup>+</sup> nTreg T cells from Nrn1<sup>-/-</sup> or ctrl were transferred with CD45.1<sup>+</sup> FDG splenocytes devoid of Tregs into Rag2<sup>-/-</sup> host. Treg cell expansion and suppression toward FDG CD45.1<sup>+</sup> responder cells were evaluated on day 7 post cell transfer. Alternatively, B16F10 tumor cells were inoculated on day 7 after cell transfer and monitored for tumor growth. (<bold>E-H</bold>) CD45.2<sup>+</sup> cell proportion (<bold>E</bold>), Foxp3 retention (<bold>F</bold>), and Ki67 expression among Foxp3<sup>+</sup> cells (<bold>G</bold>) at day 7 post cell transfer. (<bold>H</bold>) CD45.1<sup>+</sup> cell proportion and number in the spleen of Nrn1<sup>-/-</sup> or ctrl Treg hosts day 7 post cell transfer. (<bold>I-L</bold>). Treg cell suppression toward anti-tumor response. (<bold>I</bold>) Tumor growth curve and tumor size at harvest from Nrn1<sup>-/-</sup> or ctrl nTreg hosts. (<bold>J</bold>) CD45.1<sup>+</sup> cell count in tumor draining lymph node (LN) and spleen. (<bold>K</bold>) the proportion of CD45.1<sup>+</sup> cells among CD45<sup>+</sup> tumor lymphocyte infiltrates (TILs). (<bold>L</bold>) IFNγ% among CD8<sup>+</sup> T cells in TILs. n<underline>&gt;</underline>5 mice per group. (<bold>E-H</bold>) represents three independent experiments, <bold>(I-L</bold>) represents two independent experiments. Data are presented as mean <underline>+</underline>SEM *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001. Unpaired Student’s t-tests were performed.</p></caption>
<graphic xlink:href="578284v1_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>The defects observed in iTreg cell expansion <italic>in vitro</italic> prompt further examination of Nrn1<sup>-/-</sup> nTreg expansion and suppression function <italic>in vivo.</italic> To this end, we tested the suppression capacity of congenically marked (CD45.1<sup>-</sup>CD45.2<sup>+</sup>) Nrn1<sup>-/-</sup> or ctrl nTreg toward CD45.1<sup>+</sup>CD45.2<sup>-</sup> responder cells in Rag2<sup>-/-</sup> mice (<xref rid="fig2" ref-type="fig">Figure 2D</xref>). The CD45.1<sup>+</sup>CD45.2<sup>-</sup> responder cells devoid of Treg cells were splenocytes derived from Foxp3DTRGFP (FDG) mice pretreated with diphtheria toxin (DT) (<xref ref-type="bibr" rid="c33">Kim et al., 2007</xref>; <xref ref-type="bibr" rid="c78">Workman et al., 2011</xref>). DT treatment caused the deletion of Treg cells in FDG mice (<xref ref-type="bibr" rid="c33">Kim et al., 2007</xref>). Although the CD45.1<sup>-</sup>CD45.2<sup>+</sup> Nrn1<sup>-/-</sup> and ctrl cell proportions were not significantly different among hosts splenocytes at day 7 post transfer (<xref rid="fig2" ref-type="fig">Figure 2E</xref>), Nrn1<sup>-/-</sup> cells retained a higher Foxp3<sup>+</sup> cell proportion and reduced Ki67 expression comparing to the ctrl (<xref rid="fig2" ref-type="fig">Figure 2F</xref>, G). These findings were similar to our observation of iTreg cells <italic>in vitro</italic> (<xref rid="fig2" ref-type="fig">Figure 2B</xref>, C). Nrn1<sup>-/-</sup> Tregs also showed reduced suppression toward CD45.1<sup>+</sup> responder cells, evidenced by increased CD45.1<sup>+</sup> proportion and cell number in host splenocytes (<xref rid="fig2" ref-type="fig">Figure 2H</xref>).</p>
<p>To evaluate the functional implication of Nrn1<sup>-/-</sup> Treg suppression in disease settings, we challenged the Rag2<sup>-/-</sup> hosts with the poorly immunogenic B16F10 tumor (<xref rid="fig2" ref-type="fig">Figure 2D</xref>). Tumors grew much slower in Nrn1<sup>-/-</sup> Treg recipients than those reconstituted with ctrl Tregs (<xref rid="fig2" ref-type="fig">Figure 2I</xref>). Moreover, the number of CD45.1<sup>+</sup> cells in tumor-draining lymph nodes and spleens increased significantly in Nrn1<sup>-/-</sup> Treg hosts compared to the ctrl group (<xref rid="fig2" ref-type="fig">Figure 2J</xref>). Consistently, the CD45.1<sup>+</sup> responder cell proportion among tumor lymphocyte infiltrates (TILs) was also increased (<xref rid="fig2" ref-type="fig">Figure 2K</xref>), accompanied by an increased proportion of IFNγ<sup>+</sup> cells among CD8 TILs from Nrn1<sup>-/-</sup> Treg hosts (<xref rid="fig2" ref-type="fig">Figure 2L</xref>). The increased expansion of CD45.1<sup>+</sup> responder cells and reduced tumor growth further confirmed the reduced suppressive capacity of Nrn1<sup>-/-</sup> Treg cells.</p>
</sec>
<sec id="s2c">
<title>Nrn1 impacts Treg cell electrical and metabolic state</title>
<p>To understand the molecular mechanisms associated with Nrn1<sup>-/-</sup> Treg cells, we compared gene expression between Nrn1<sup>-/-</sup> and ctrl iTregs under resting (IL2 only) and activation (aCD3 and IL2) conditions by RNASeq. GSEA on gene ontology database and clustering of enriched gene sets by Cytoscape identified three clusters enriched in resting Nrn1<sup>-/-</sup> iTreg (<xref rid="fig3" ref-type="fig">Figure 3A</xref>, Figure 3-figure supplement Table 1)(<xref ref-type="bibr" rid="c64">Shannon et al., 2003</xref>; <xref ref-type="bibr" rid="c70">Subramanian et al., 2005</xref>). The “neurotransmitter involved in membrane potential (MP)” and “sodium transport” clusters involved gene sets on the ion transport and cell MP regulation (<xref rid="fig3" ref-type="fig">Figure 3A</xref>, Figure 3-figure supplement Table 1). MP is the difference in electric charge between the interior and the exterior of the cell membrane (<xref ref-type="bibr" rid="c1">Abdul Kadir et al., 2018</xref>; <xref ref-type="bibr" rid="c5">Blackiston et al., 2009</xref>; <xref ref-type="bibr" rid="c41">Ma et al., 2017</xref>). Ion channels and transporters for Na<sup>+</sup> and other ions such as K<sup>+</sup>, Cl<sup>-</sup> <italic>et al</italic>. maintain the ion balance and contribute to cell MP (<xref ref-type="bibr" rid="c5">Blackiston et al., 2009</xref>). MP change can impact cell plasma membrane lipid dynamics and affect receptor kinase activity (<xref ref-type="bibr" rid="c85">Zhou et al., 2015</xref>). The enrichment of “receptor protein kinase” gene set clusters may reflect changes caused by MP (<xref rid="fig3" ref-type="fig">Figure 3A</xref>, Figure 3-figure supplement Table 1). Gene set cluster analysis on activated iTreg cells also revealed the enrichment of the “ion channel and receptor” cluster in Nrn1<sup>-/-</sup> cells (<xref rid="fig3" ref-type="fig">Figure 3B</xref>, Figure 3-figure supplement table 2), supporting the potential role of Nrn1 in modulating ion balances and MP.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Nrn1 expression impacts Treg cell electrical and metabolic state.</title>
<p>(<bold>A-C</bold>). Gene sets clusters enriched in Nrn1<sup>-/-</sup> and ctrl iTreg cells. Gene sets cluster analysis via Cytoscape was performed on Gene ontology Molecular Function (GO_MF) gene sets. The results cutoff: p-value <underline>&lt;</underline>0.05 and FDR q-value <underline>&lt;</underline>0.1. (<bold>A</bold>) Gene sets cluster in Nrn1<sup>-/-</sup> iTreg cells cultured under resting condition (IL2 only) (Figure 3-figure supplement Table 1). (<bold>B</bold>) Gene sets clusters in Nrn1<sup>-/-</sup> and ctrl iTreg cells reactivated with anti-CD3 (Figure 3-figure supplement Table 2). (<bold>C</bold>) Comparison of enriched gene sets in Nrn1<sup>-/-</sup> under resting vs. activating condition (Figure 3-figure supplement Table 3). (<bold>D-F)</bold> Changes relating to cell electric state. (<bold>D</bold>) Enrichment of “GOMF_Neurotransmitter receptor activity involved in the regulation of postsynaptic membrane potential” gene set and enriched gene expression heatmap. (<bold>E</bold>) Membrane potential was measured in Nrn1<sup>-/-</sup> and ctrl iTreg cells cultured in IL2 or activated with anti-CD3 in the presence of IL2. Data represent three independent experiments. (<bold>F</bold>) Enrichment of “GOMF_Metal ion transmembrane transporter activity” gene set and enriched gene expression heatmap (Figure 3- figure supplement 1A). (<bold>G-K</bold>). Metabolic changes associated with Nrn1<sup>-/-</sup> iTreg. (<bold>G</bold>) Heatmap of differentially expressed amino acid (AA) transport-related genes (from “MF_Amino acid transmembrane transporter activity” gene list) in Nrn1<sup>-/-</sup> and ctrl iTreg cells. (<bold>H</bold>) pmTOR and pS6 levels in TCR activated iTreg cells measured by flow cytometry. n=3 replicates per group. Data represent three independent experiments. (<bold>I</bold>) Measurement of pmTOR and pS6 in iTreg cells that were deprived of nutrients for 1h and refed with RPMI for two hours. (<bold>J</bold>) Hallmark gene sets significantly enriched in Nrn1<sup>-/-</sup> and ctrl iTreg. NOM p-val&lt;0.05, FDR q-val&lt;0.25. (<bold>K</bold>) Seahorse analysis of extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) in Nrn1<sup>-/-</sup> and ctrl iTreg cells. n=6∼10 technical replicates per group. Data represent three independent experiments. **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001. Unpaired student t-test for two-group comparison. Unpaired t-test (H, K), two-way ANOVA (E, I). ns, not significant.</p></caption>
<graphic xlink:href="578284v1_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>The “Neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential” gene set was significantly enriched under resting and activation conditions (<xref rid="fig3" ref-type="fig">Figure 3C and D</xref>; Figure 3-figure supplement Table 3). The α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid receptor (AMPAR) subunits Gria2 and Gria3 are the major components of this gene set and showed increased expression in Nrn1<sup>-/-</sup> cells (<xref rid="fig3" ref-type="fig">Figure 3D</xref>). AMPAR is an ionotropic glutamate receptor that mediates fast excitatory synaptic transmission in neurons. Nrn1 has been reported as an accessory protein for AMPAR (<xref ref-type="bibr" rid="c52">Pandya et al., 2018</xref>; <xref ref-type="bibr" rid="c63">Schwenk et al., 2012</xref>; <xref ref-type="bibr" rid="c71">Subramanian et al., 2019</xref>), although the functional implication of Nrn1 as an AMPAR accessory protein remains unclear. The enrichment of MP related gene set prompted the examination of electric status, including MP level and ion channel expressions. We examined the relative MP level by FLIPR MP dye, a lipophilic dye able to cross the plasma membrane, which has been routinely used to measure cell MP changes (<xref ref-type="bibr" rid="c18">Dvorak et al., 2021</xref>; <xref ref-type="bibr" rid="c30">Joesch et al., 2008</xref>; <xref ref-type="bibr" rid="c48">Nik et al., 2017</xref>; <xref ref-type="bibr" rid="c77">Whiteaker et al., 2001</xref>). When the cells are depolarized, the dye enters the cells, causing an increase in fluorescence signal. Conversely, cellular hyperpolarization results in dye exit and decreased fluorescence. Compared to ctrl iTreg cells, Nrn1<sup>-/-</sup> exhibits significant hyperpolarization under both resting and activation conditions (<xref rid="fig3" ref-type="fig">Figure 3E</xref>). Consistent with the MP change, the “MF_metal ion transmembrane transporter activity” gene set, which contains 436 ion channel related genes, was significantly enriched and showed a different expression pattern in Nrn1<sup>-/-</sup> iTregs (<xref rid="fig3" ref-type="fig">Figure 3F</xref>; Figure 3-figure supplement 1A and B). The changes in cellular MP and differential expression of ion channel and transporter genes in Nrn1<sup>-/-</sup> implicate the role of Nrn1 in the balance of electric state in the iTreg cell.</p>
<p>MP changes have been associated with changes in amino acid (AA) transporter expression and nutrient acquisition, which in turn influences cellular metabolic and functional state (<xref ref-type="bibr" rid="c80">Yu et al., 2022</xref>). To understand whether MP changes in Nrn1<sup>-/-</sup> are associated with changes in nutrient acquisition and thus the metabolic state, we surveyed AA transport-related gene expression using the “Amino acid transmembrane transporter activity” gene set and found differential AA transporter gene expression between Nrn1<sup>-/-</sup> and ctrl iTregs (<xref rid="fig3" ref-type="fig">Figure 3G</xref>). Electrolytes and AAs entry are critical regulators of mTORC1 activation and T cell metabolism (<xref ref-type="bibr" rid="c38">Liu and Sabatini, 2020</xref>; <xref ref-type="bibr" rid="c59">Saravia et al., 2020</xref>; <xref ref-type="bibr" rid="c68">Sinclair et al., 2013</xref>; <xref ref-type="bibr" rid="c76">Wang et al., 2020</xref>). We examined mTORC1 activation at the protein level by evaluating mTOR and S6 phosphorylation via flow cytometry. We found reduced phosphorylation of mTOR and S6 in activated Nrn1<sup>-/-</sup> iTreg cells (<xref rid="fig3" ref-type="fig">Figure 3H</xref>). We further performed a nutrient-sensing assay to evaluate the role of ion and nutrient entry in mTORC1 activation. Nrn1<sup>-/-</sup> and ctrl iTreg cells were starved for one hour in a nutrient-free buffer, followed by adding RPMI medium with complete ions and nutrients, and cultured for two more hours. While adding the medium with nutrients clearly increased the mTOR and S6 phosphorylation, the degree of change was significantly less in Nrn1<sup>-/-</sup> than in the ctrl (<xref rid="fig3" ref-type="fig">Figure 3I</xref>). Consistently, GSEA on Hallmark gene sets reveal reduced gene set enrichment relating to the mTORC1 signaling, corroborating the reduced pmTOR and pS6 detection in Nrn1<sup>-/-</sup> cells. Moreover, Nrn1<sup>-/-</sup> cells also showed reduced expression of glycolysis, fatty acid metabolism, and oxidative phosphorylation related gene sets under both resting and activating conditions (<xref rid="fig3" ref-type="fig">Figure 3J</xref>, Figure 3-figure supplement 1C), indicating changes in metabolic status. Since previous work has identified mTORC1 to be an important regulator of aerobic glycolysis and given that our GSEA data suggested changes in glycolysis (<xref rid="fig3" ref-type="fig">Figure 3J</xref>) (<xref ref-type="bibr" rid="c58">Salmond, 2018</xref>), we performed the seahorse assay and confirmed reduced glycolysis among Nrn1<sup>-/-</sup> cells (<xref rid="fig3" ref-type="fig">Figure 3K</xref>). Examination of mitochondrial bioenergetic function revealed a similar oxygen consumption rate (OCR) between Nrn1<sup>-/-</sup> and ctrl cells (<xref rid="fig3" ref-type="fig">Figure 3K</xref>). Thus, Nrn1 expression can affect the iTreg electric state, influence ion channel and nutrient transporter expression, impact nutrient sensing, modulate metabolic state, and contribute to Treg expansion and suppression function.</p>
</sec>
<sec id="s2d">
<title>Nrn1 impact effector T cell inflammatory response</title>
<p>CD4<sup>+</sup> T cells can pass through an effector stage on their way to an anergic state (<xref ref-type="bibr" rid="c27">Huang et al., 2003</xref>). Since Nrn1 expression is significantly induced after T cell activation (<xref rid="fig1" ref-type="fig">Figure 1D</xref>), Nrn1 might influence CD4<sup>+</sup> effector (Te) cell differentiation, affecting anergy development. Nrn1 may exert different electric changes due to distinct ion channel expression contexts in Te cells than in Tregs. We first evaluated Nrn1<sup>-/-</sup> Te cell differentiation <italic>in vitro.</italic> Nrn1 deficient CD4 Te cells showed increased Ki67 expression, associated with increased cytokine TNFα, IL2, and IFNγ expression upon restimulation (<xref rid="fig4" ref-type="fig">Figure 4A</xref>). To evaluate Nrn1<sup>-/-</sup> Te cell response <italic>in vivo</italic>, we crossed Nrn1<sup>-/-</sup> with FDG mice and generated Nrn1<sup>-/-</sup>_FDG and ctrl_FDG mice, which enabled the elimination of endogenous Treg cells (<xref rid="fig4" ref-type="fig">Figure 4B</xref>). Deleting endogenous Foxp3<sup>+</sup> Treg cells using DT will cause the activation of self-reactive T cells, leading to an autoimmune response (<xref ref-type="bibr" rid="c33">Kim et al., 2007</xref>; <xref ref-type="bibr" rid="c49">Nystrom et al., 2014</xref>). Upon administration of DT, we observed accelerated weight loss in Nrn1<sup>-/-</sup>_FDG mice, reflecting enhanced autoimmune inflammation (<xref rid="fig4" ref-type="fig">Figure 4C</xref>). Examination of T cell response revealed a significant increase in Ki67 expression and inflammatory cytokine TNFα, IL2, and IFNγ expression among Nrn1<sup>-/-</sup> CD4 cells on day 6 post DT treatment (<xref rid="fig4" ref-type="fig">Figure 4D</xref>), consistent with the findings <italic>in vitro</italic>. The proportion of Foxp3<sup>+</sup> cells was very low on day 6 post DT treatment and comparable between Nrn1<sup>-/-</sup> and the ctrl (<xref rid="fig4" ref-type="fig">Figure 4E</xref>), suggesting that the differential Te cell response was not due to the impact from Treg cells. Thus, Nrn1 deficiency enhances Te cell response <italic>in vitro</italic> and <italic>in vivo</italic>.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4.</label>
<caption><title>Nrn1 deficiency affects Te cell response.</title>
<p>(<bold>A</bold>) Comparison of cell proliferation and cytokine expression in Nrn1<sup>-/-</sup> and ctrl Te cells. Data represent one of three independent experiments. (<bold>B-E</bold>) An enhanced autoimmune response in Nrn1<sup>-/-</sup> mice <italic>in vivo</italic>. (<bold>B</bold>) Experimental scheme. Nrn1<sup>-/-</sup> mice were crossed with FDG mice and Nrn1-/-_FDG or ctrl_FDG mice were obtained. The autoimmune response was induced by injecting DT i.p. to delete endogenous Treg cells. Mice’s weight change was monitored after disease induction. (<bold>C</bold>) Relative body weight change after autoimmune response induction. (<bold>D</bold>) Mice were harvested 6 days after DT injection and assessed for ki67, cytokine TNFα, IL2, and IFNγ expression in CD4<sup>+</sup> cells. (<bold>E</bold>) Foxp3 expression among CD4<sup>+</sup> cells day 6 post DT treatment. n<underline>&gt;</underline>5 mice per group. Data represent four independent experiments. (<bold>F-I</bold>) Changes relating to ion balances in Te cells. (<bold>F</bold>) Gene sets clusters from GSEA of GO_MF and GO_Biological process (GO_BP) results in Nrn1<sup>-/-</sup> and ctrl Te cells (Figure 4-figure supplement Table 4). (<bold>G</bold>) Enrichment of “GOBP_ membrane repolarization” gene set and enriched gene expression heatmap. (<bold>H</bold>) Membrane potential measurement in Te cells. Data represent two independent experiments. (<bold>I</bold>) Enrichment of “GOMF_Metal ion transmembrane transporter activity” gene set and heatmap of differential gene expression pattern (Figure 4-figure supplement 1B). (<bold>J-N</bold>) Metabolic changes associated with Nrn1<sup>-/-</sup> Te cell. (<bold>J</bold>) Enrichment of “GOMF_amino acid transmembrane transporter activity” gene set and differential gene expression heatmap. (<bold>K</bold>) Phosphorylation of mTOR and S6 in Te cells measured by flow cytometry. n=3 replicates per group. Data represent two independent experiments. (<bold>L</bold>) Measurement of pmTOR and pS6 in Te cells after nutrient sensing. Data represent three independent experiments. (<bold>M</bold>) Enriched Hallmark gene sets (p&lt;0.05, FDR q&lt;0.25). (<bold>N</bold>) Seahorse analysis of extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) in Nrn1<sup>-/-</sup> and ctrl Te cells. n<underline>&gt;</underline>6 technical replicates per group. Data represent three independent experiments. Error bars indicate <underline>+</underline>SEM. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001, unpaired Student’s t-test was performed for two-group comparison.</p></caption>
<graphic xlink:href="578284v1_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>To identify molecular changes responsible for Nrn1<sup>-/-</sup> Te phenotype, we compared gene expression between Nrn1<sup>-/-</sup> and ctrl Te cells by RNASeq. GSEA and Cytoscape analysis identified a cluster of gene sets on “membrane repolarization”, suggesting that Nrn1 may also be involved in the regulation of MP under Te context (<xref rid="fig4" ref-type="fig">Figure 4F</xref>, Figure 4-figure supplement Table 4) (<xref ref-type="bibr" rid="c64">Shannon et al., 2003</xref>; <xref ref-type="bibr" rid="c70">Subramanian et al., 2005</xref>). While the “membrane_repolarization” gene set was enriched in Nrn1<sup>-/-</sup> (<xref rid="fig4" ref-type="fig">Figure 4G</xref>), the “Neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential” gene set was no longer enriched, but the AMPAR subunit Gria3 expression was still elevated in Nrn1<sup>-/-</sup> Te cells (Figure 4-figure supplement 1A). Although MP in Te cells was comparable between Nrn1<sup>-/-</sup> and ctrl (<xref rid="fig4" ref-type="fig">Figure 4H</xref>), the “MF_metal ion transmembrane transporter activity” gene set was significantly enriched in Nrn1<sup>-/-</sup> with different gene expression patterns (<xref rid="fig4" ref-type="fig">Figure 4I</xref>, Figure 4-figure supplement 1B), indicative of different electric state. The significant enrichment of ion channel related genes in Nrn1<sup>-/-</sup> Te cells was in line with the finding in Nrn1<sup>-/-</sup> iTreg cells, supporting the notion that Nrn1 expression may be involved in ion balance and MP modulation.</p>
<p>Examination of nutrient transporters revealed that the “Amino acid transmembrane transporter activity” gene set was significantly enriched in Nrn1<sup>-/-</sup> cells than the ctrl (<xref rid="fig4" ref-type="fig">Figure 4J</xref>). Along with the enrichment of ion channel and nutrient transporter genes (<xref rid="fig4" ref-type="fig">Figure 4I and J</xref>), we found enhanced mTOR and S6 phosphorylation in Nrn1<sup>-/-</sup> Te cells (<xref rid="fig4" ref-type="fig">Figure 4K</xref>). We also compared nutrient sensing capability between Nrn1<sup>-/-</sup> and ctrl Te cells, as outlined in <xref rid="fig3" ref-type="fig">Figure 3I</xref>. Nrn1<sup>-/-</sup> Te showed increased mTOR and S6 phosphorylation after sensing ions and nutrients in RPMI medium (<xref rid="fig4" ref-type="fig">Figure 4L</xref>), confirming the differential impact of ions and nutrients on Nrn1<sup>-/-</sup> and ctrl Te cells. GSEA on Hallmark collection showed enrichment of mTORC1 signaling gene set (<xref rid="fig4" ref-type="fig">Figure 4M</xref>), corroborating with increased pmTOR and pS6 detection in Nrn1<sup>-/-</sup> Te cells. Along with increased mTORC1 signaling, Nrn1<sup>-/-</sup> Te cells also showed enrichment of gene sets on glycolysis and proliferation (<xref rid="fig4" ref-type="fig">Figure 4M</xref>). Evaluation of metabolic changes by seahorse confirmed increased glycolysis in Nrn1<sup>-/-</sup> cells, while the OCR remained comparable between Nrn1<sup>-/-</sup> and ctrl (<xref rid="fig4" ref-type="fig">Figure 4N</xref>). These <italic>in vitro</italic> studies on Te cells indicate that Nrn1 deficiency resulted in the dysregulation of the electrolyte and nutrient transport program, impacting Te cell nutrient sensing, metabolic state, and the outcome of inflammatory response.</p>
</sec>
<sec id="s2e">
<title>Nrn1 deficiency exacerbates autoimmune disease</title>
<p>The coordinated reaction of Treg and Te cells contributes to the outcome of the immune response. We employed the experimental autoimmune encephalomyelitis (EAE), the murine model of multiple sclerosis (MS) to evaluate the overall impact of Nrn1 on autoimmune disease development. Upon EAE induction, the incidence and time to EAE onset in Nrn1<sup>-/-</sup> mice were comparable to the ctrl mice, but the severity, disease persistence, and body weight loss were increased in Nrn1<sup>-/-</sup> mice (<xref rid="fig5" ref-type="fig">Figure 5A</xref>). Exacerbated EAE was associated with significantly increased CD45<sup>+</sup> cell infiltrates, increased CD4<sup>+</sup> cell number, increased proportion of MOG-specific CD4 cells, and reduced proportion of Foxp3<sup>+</sup> CD4 cells in the Nrn1<sup>-/-</sup> spinal cord (<xref rid="fig5" ref-type="fig">Figure 5B-E</xref>). Moreover, we also observed increased proportions of IFN7<sup>+</sup> and IL17<sup>+</sup> CD4 cells in Nrn1<sup>-/-</sup> mice (<xref rid="fig5" ref-type="fig">Figure 5F</xref>). Thus, the results from EAE corroborated with earlier data and confirmed the important role of Nrn1 in establishing immune tolerance and modulating autoimmunity.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5.</label>
<caption><title>Nrn1 deficiency exacerbates autoimmune EAE disease.</title>
<p>(<bold>A</bold>) Aggravated body weight loss and protracted EAE disease in Nrn1<sup>-/-</sup> mice. (<bold>B</bold>) CD45<sup>+</sup> cell number in the spinal cord infiltrates. (<bold>C</bold>) CD4<sup>+</sup> cell number in the spinal cord infiltrates. (<bold>D</bold>) Mog<sub>38-49</sub>/IA<sup>b</sup> tetramer staining of spinal cord infiltrating CD4 cells. (<bold>E</bold>) Foxp3<sup>+</sup> proportion among CD4<sup>+</sup> cells in spinal cord infiltrates. (<bold>F</bold>) IFNγ<sup>+</sup> and IL17<sup>+</sup> cell proportion among CD4<sup>+</sup> cells in draining lymph nodes. n<underline>&gt;</underline>5 mice per group. Data represent three independent experiments. The P value was calculated by 2way ANOVA for (<bold>A</bold>). The p-value was calculated by the unpaired student t-test for (<bold>B-F</bold>). *<italic>P</italic>&lt;0.05, **<italic>P</italic>&lt;0.01.</p></caption>
<graphic xlink:href="578284v1_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>T cell expansion and functional development depend on adaptive electric and metabolic changes, maintaining electrolyte balances, and appropriate nutrient uptake. The negative charge of the plasma membrane, ion channel expression pattern, and function are key characteristics associated with the cellular electric state in different systems, impacting cell proliferation and function (<xref ref-type="bibr" rid="c5">Blackiston et al., 2009</xref>; <xref ref-type="bibr" rid="c20">Emmons-Bell and Hariharan, 2021</xref>; <xref ref-type="bibr" rid="c32">Kiefer et al., 1980</xref>; <xref ref-type="bibr" rid="c46">Monroe and Cambier, 1983</xref>; <xref ref-type="bibr" rid="c73">Sundelacruz et al., 2009</xref>). The electrolytes and nutrients, including amino acids, metabolites, and small peptides transported through ion channels and nutrient transporters, are also regulators and signaling agents impacting the choice of cellular metabolic pathways and functional outcomes (<xref ref-type="bibr" rid="c26">Hamill et al., 2020</xref>). In this study, we report that the neurotropic factor Nrn1 expression influences CD4 T cell MP, ion channels, and nutrient transporter expression patterns, contributing to differential metabolic states in Treg and Te cells. Nrn1 deficiency compromises Treg cell expansion and suppression while enhancing Te cell inflammatory response, exacerbating autoimmune disease.</p>
<p>Bioelectric controls have been defined as a type of epigenetics that can control information residing outside of genomic sequence (<xref ref-type="bibr" rid="c35">Levin, 2021</xref>). The sum of ion channels and pump activity generates the ionic gradient across the cell membrane, establishing the MP level and bioelectric state. Cells with the same MP can have different ion compositions, and the same ion channel may have a differential impact on MP when in combination with different ion channels (<xref ref-type="bibr" rid="c1">Abdul Kadir et al., 2018</xref>). Consistent with this notion, Nrn1 deficiency has differential impacts on the cellular electric state under the Treg and Te cells with different ion channel combinations. Altered MP was detected in Nrn1 deficient Treg cells (<xref rid="fig3" ref-type="fig">Figure 3E</xref>), while comparable MP was observed between Nrn1<sup>-/-</sup> and ctrl Te cells (<xref rid="fig4" ref-type="fig">Figure 4H</xref>). The MP level determined by ion channels and pump activity can influence the nutrient transport pattern, establishing a metabolic and functional state matching the MP level (<xref ref-type="bibr" rid="c5">Blackiston et al., 2009</xref>; <xref ref-type="bibr" rid="c20">Emmons-Bell and Hariharan, 2021</xref>; <xref ref-type="bibr" rid="c32">Kiefer et al., 1980</xref>; <xref ref-type="bibr" rid="c46">Monroe and Cambier, 1983</xref>; <xref ref-type="bibr" rid="c73">Sundelacruz et al., 2009</xref>; <xref ref-type="bibr" rid="c80">Yu et al., 2022</xref>). Yu et al. reported that macrophage MP modulates plasma membrane phospholipid dynamics and facilitates cell surface retention of nutrient transporters, thus supporting nutrient uptake and impacting the inflammatory response (<xref ref-type="bibr" rid="c80">Yu et al., 2022</xref>). Nutrient transport is key to T cell fate decisions and has been considered signal 4 to T cell fate choices (<xref ref-type="bibr" rid="c11">Chapman and Chi, 2022</xref>; <xref ref-type="bibr" rid="c39">Long et al., 2021</xref>). The changes in ion channel related gene expression and MP level in Nrn1<sup>-/-</sup> cells were accompanied by differential expression of AA transporter genes and nutrient sensing activity that impacted mTORC1 pathway activation and cellular glycolytic state (<xref rid="fig3" ref-type="fig">Figures 3</xref> and <xref rid="fig4" ref-type="fig">4</xref>). These results corroborate previous observations on the connection of MP in nutrient acquisition and metabolic change and support the role of Nrn1 in coordinating T cell electric and metabolic adaptation (<xref ref-type="bibr" rid="c80">Yu et al., 2022</xref>).</p>
<p>Although Nrn1, as a small GPI-anchored protein, does not have channel activity by itself, it has been identified as one of the components in the AMPAR complex (<xref ref-type="bibr" rid="c52">Pandya et al., 2018</xref>; <xref ref-type="bibr" rid="c63">Schwenk et al., 2012</xref>; <xref ref-type="bibr" rid="c71">Subramanian et al., 2019</xref>). Na<sup>+</sup>-influx through the AMPA type ionotropic glutamate receptor can quickly depolarize the postsynaptic compartment and potentiate synaptic transmission in neurons. We have observed increased expression of AMPAR subunits in Nrn1<sup>-/-</sup> iTreg and Te cells (<xref rid="fig3" ref-type="fig">Figure 3D</xref>, Figure 4-figure supplement 1), implicating potential change in AMPAR activity in Nrn1<sup>-/-</sup> under Treg and Te cell context. Glutamate secreted by proliferating cells may influence T cell function through AMPAR. High glutamate levels are detected at the autoimmune disease site and tumor interstitial fluid (<xref ref-type="bibr" rid="c7">Bonnet et al., 2020</xref>; <xref ref-type="bibr" rid="c43">McNearney et al., 2004</xref>; <xref ref-type="bibr" rid="c72">Sullivan et al., 2019</xref>). Moreover, AMPAR has been implicated in exacerbating autoimmune disease (<xref ref-type="bibr" rid="c8">Bonnet et al., 2015</xref>; <xref ref-type="bibr" rid="c60">Sarchielli et al., 2007</xref>). The increased expression of AMPAR subunits in Nrn1<sup>-/-</sup> cells supports the potential connection of Nrn1 and AMPAR and warrants future investigation on the possibility that Nrn1 functions through AMPAR, impacting T cell electric change. Besides AMPAR, Nrn1 has been reported to function through the insulin receptor and fibroblast growth factor pathway (<xref ref-type="bibr" rid="c65">Shimada et al., 2016</xref>; <xref ref-type="bibr" rid="c79">Yao et al., 2012</xref>). Subramanian et al have suggested that rather than a traditional ligand with its cognate receptor, Nrn1 may function as an adaptor to receptors to perform diverse cell-type-specific functions (<xref ref-type="bibr" rid="c71">Subramanian et al., 2019</xref>). Our results do not rule out these possibilities.</p>
<p>Overall, we found that Nrn1 expression in Treg and Te cells can impact cellular electric state, nutrient sensing, and metabolism in a cell context dependent manner. The predominant enrichment of ion channel related gene sets in both Treg and Te cell context underscores the importance of Nrn1 in modulating ion balance and MP. The changes in ion channels and nutrient transporter expression in Treg and Te cells and associated functional consequences highlight the importance of Nrn1 in coordinating cell metabolic changes through channels and transporters during the adaptive response and contribute to the balance of tolerance and immunity.</p>
</sec>
<sec id="s4">
<title>Materials and Methods</title>
<sec id="s4a">
<title>Mouse models</title>
<p>The Nrn1<sup>-/-</sup> mice (<xref ref-type="bibr" rid="c23">Fujino et al., 2011</xref>), Foxp3DTRGFP (FDG)(<xref ref-type="bibr" rid="c33">Kim et al., 2007</xref>), and TCRα<sup>-/-</sup> mice were obtained from the Jackson Laboratory. OTII mice on Thy1.1<sup>+</sup> background was kindly provided by Dr. Jonathan Powell. Rag2<sup>-/-</sup> mice were maintained in our mouse facility. 6.5 TCR transgenic mice specific for HA antigen and C3HA mice (both on the B10.D2 background) have been described previously (<xref ref-type="bibr" rid="c28">Huang et al., 2004</xref>). Nrn1<sup>-/-</sup> mice were crossed with OTII mice to generate Nrn1<sup>-/-</sup>_OTII<sup>+</sup> mice, ctrl_OTII<sup>+</sup> mice. Nrn1<sup>-/-</sup> mice were also crossed with FDG mice to generate Nrn1<sup>-/-</sup>_FDG and ctrl_FDG mice. All mice colonies were maintained in accordance with the guidelines of Johns Hopkins University and the institutional animal care and use committee</p>
</sec>
<sec id="s4b">
<title>Antibodies and Reagents</title>
<p>We have used the following antibodies: Anti-CD3 (17A2), anti-CD4 (RM4-5), anti-CD8a (53-6.7), anti-CD25 (PC61), anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD62L (MEL-14), CD73 (TY/111.8), anti-CD90.1 (OX-7), anti-CD90.2 (30-H12), anti-TCR V775.1, 5.2 (MR9-4), anti-PD1 (29F.1A12), anti-IFNγ (XMG1.2), anti-IL17α (TC11-18H10.1), anti-TNFα (MP6-XT22), anti-Tbet (4B10), anti-Ki67 (16A8) were purchased from Biolegend. Anti-CD44 (IM7), CD45 (30-F11), anti-CD69(H1.2F3) were purchased from BD Bioscience. Anti-FOXP3 (FJK-16s) was purchased from eBioscience. The flow cytometry data were collected using BD Celesta (BD Biosciences) or Attune Flow Cytometers (ThermoFisher). Data were analyzed using FlowJo (Tree Star) software.</p>
<p>Mouse monoclonal anti-Nrn1 antibody (Ab) against Nrn1 was custom-made (A&amp;G Pharmaceutical). The specificity of anti-Nrn1 Ab was confirmed by ELISA, cell surface staining of Nrn1 transfected 293T cells, and western blot of Nrn1 recombinant protein and brain protein lysate from WT mice or Nrn1<sup>-/-</sup> mice (data not shown). OVA<sub>323-339</sub> peptide and MOG<sub>35-55</sub> was purchased from GeneScript. Incomplete Freund’s adjuvant (IFA) and Mycobacterium tuberculosis H37Ra (killed and desiccated) were purchased from Difco. Pertussis toxin was purchased from List Biological Laboratories and diphtheria toxin was obtained from Millipore-Sigma.</p>
</sec>
<sec id="s4c">
<title>Cell purification and culture</title>
<p>Naïve CD4 cells were isolated from the spleen and peripheral lymph node by a magnetic bead-based purification according to the manufacturer’s instruction (Miltenyi Biotech). Purified CD4 cells were stimulated with plate-bound anti-CD3 (5ug/ml, Bio-X-Cell) and anti-CD28 (2ug/ml, Bio-X-Cell) for 3 days, in RPMI1640 medium supplemented with 10%FBS, HEPES, penicillin/streptomycin, MEM Non-Essential Amino Acids, and β-mercaptoethanol. For iTreg cell differentiation, cells were stimulated in the presence of human IL2 (100u/ml, PeproTech), human TGF² (10ng/ml, PeproTech), anti-IL4, and anti-IFNγ antibody (5ug/ml, Clone 11B11 and clone XMG1.2, Bio-X-Cell) in 10% RPMI medium. CD4<sup>+</sup> Te cells were differentiated without additional cytokine or antibody for three days, followed by additional culture for 2 days in IL2 100u/ml in 10%RPMI medium. nTreg cells were isolated by sorting from the FDG CD4<sup>+</sup> fraction based on Foxp3<sup>+</sup>GFP and CD25 expression (CD4<sup>+</sup>CD25<sup>+</sup>GFP<sup>+</sup>). Alternatively, nTreg cells were enriched from CD4 cells by positive selection using the CD4<sup>+</sup>CD25<sup>+</sup> Regulatory T Cell Isolation Kit from Miltenyi.</p>
</sec>
<sec id="s4d">
<title>Self-antigen induced tolerance model</title>
<p>1x10<sup>6</sup> HA-specific Thy1.1<sup>+</sup> 6.5 CD4 cells from donor mice on a B10.D2 background were transferred into C3-HA recipient mice, where HA is expressed as self-antigen in the lung; or into WT B10.D2 mice followed by infection with Vac-HA virus (1x10<sup>6</sup> pfu). HA-reactive T cells were recovered from the lung-draining lymph node of C3-HA host mice or WT B10.D2 Vac-HA infected mice at indicated time points by cell sorting. RNA from sorted cells was used for qRT-PCR assay examining Nrn1 expression.</p>
</sec>
<sec id="s4e">
<title>Peptide-induced T cell anergy model</title>
<p>5x10<sup>5</sup> Polyclonal Treg cells from CD45.1<sup>+</sup> C57BL/6 mice were mixed with 5x10<sup>6</sup> thy1.1<sup>+</sup> OTII cells from Nrn1<sup>-/-</sup>_OTII or ctrl_OTII mice and transferred by <italic>i.v.</italic> injection into TCRα<sup>-/-</sup> mice. 100ug of OVA<sub>323–339</sub> dissolved in PBS was administered <italic>i.v.</italic> on days 1, 4, and 7 after cell transfer. Host mice were harvested on day 13 after cell transfer, and cells from the lymph node and spleen were further analyzed.</p>
</sec>
<sec id="s4f">
<title><italic>In vivo</italic> Treg suppression assay</title>
<p>nTreg cells from CD45.2<sup>+</sup>CD45.1<sup>-</sup> Nrn1<sup>-/-</sup> or ctrl mice (5x10<sup>5</sup>/mouse) in conjunction with CD45.1<sup>+</sup> splenocytes (2x10<sup>6</sup>/mouse) from FDG mice were cotransferred i.p. into Rag2<sup>-/-</sup> mice. The CD45.1<sup>+</sup> splenocytes were obtained from FDG mice pretreated with DT for 2 days to deplete Treg cells. Treg suppression toward CD45.1<sup>+</sup> responder cells was assessed on day 7 post cell transfer. Alternatively, 7 days after cell transfer, Rag2<sup>-/-</sup> hosts were challenged with an <italic>i.d.</italic> inoculation of B16F10 cells (1x10<sup>5</sup>). Tumor growth was monitored daily. Treg-mediated suppression toward anti-tumor response was assessed by harvesting mice day 18-21 post-tumor inoculation.</p>
</sec>
<sec id="s4g">
<title>Induction of autoimmunity by transient Treg depletion</title>
<p>To induce autoimmunity in Nrn1<sup>-/-</sup>_FDG and ctrl_FDG mice, 1ug/mouse of DT was administered i.p. for two consecutive days, and the weight loss of treated mice was observed over time.</p>
</sec>
<sec id="s4h">
<title>EAE induction</title>
<p>EAE was induced in mice by subcutaneous injection of 200 μg MOG<sub>35–55</sub> peptide with 500 μg M. tuberculosis strain H37Ra (Difco) emulsified in incomplete Freund Adjuvant oil in 200ul volume into the flanks at two different sites. In addition, the mice received 400 ng pertussis toxin (PTX; List Biological Laboratories) <italic>i.p</italic>. at the time of immunization and 48 h later. Clinical signs of EAE were assessed daily according to the standard 5-point scale (<xref ref-type="bibr" rid="c45">Miller et al., 2007</xref>): normal mouse; 0, no overt signs of disease; 1, limp tail; 2, limp tail plus hindlimb weakness; 3, total hindlimb paralysis; 4, hindlimb paralysis plus 75% of body paralysis (forelimb paralysis/weakness); 5, moribund.</p>
</sec>
<sec id="s4i">
<title><italic/>ELISA</title>
<p>MaxiSorp ELISA plates (ThermoScientific Nunc) were coated with 100 μl of 1μg/ml anti-mIL-2 (BD Pharmingen #554424) at 4°C overnight. Coated plates were blocked with 200μl of blocking solution (10%FBS in PBS) for 1hr at room temperature (RT) followed by incubation of culture supernatant and mIL-2 at different concentrations as standard. After 1hr, plates were washed and incubated with anti-mIL-2-biotin (BD Pharmingen #554426) at RT for 1hr. After 1hr, plates were incubated with 100μl of horseradish peroxidase-labeled avidin (Vector Laboratory, #A-2004) 1μg/ml for 30min. After washing, samples were developed using the KPL TMB Peroxidase substrate system (Seracare #5120-0047) and read at 405 or 450 nm after the addition of the stop solution.</p>
</sec>
<sec id="s4j">
<title>Quantitative RT-PCR</title>
<p>RNA was isolated using the RNeasy Micro Kit (Qiagen 70004) following the manufacturer’s instructions. RNA was converted to cDNA using the High-Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific #4368814) according to the manufacturer’s instructions. The primers of murine genes were purchased from Integrated DNA Technology (IDT). qPCR was performed using the PowerUp SYBR Green Master Mix (ThermoFisher Scientific #A25780) and the Applied Biosystems StepOnePlus 96-well real-time PCR system. Gene expression levels were calculated based on the Delta-Delta Ct relative quantification method. Primers used for Nrn1 PCR were as follows: GCGGTGCAAATAGCTTACCTG (forward); CGGTCTTGATGTTCGTCTTGTC (reverse).</p>
</sec>
<sec id="s4k">
<title>Ca<sup>++</sup> flux and Membrane potential measurement</title>
<p>To measure Ca<sup>++</sup> flux, CD4 cells were loaded with Fluo4 dye at 2μM in the complete cell culture medium at 37°C for 30min. Cells were washed and resuspended in HBSS Ca<sup>++</sup> free medium and plated into 384 well glass bottom assay plate (minimum of 4 wells per sample). Ca<sup>++</sup> flux was measured using the FDSS6000 system (Hamamatsu Photonics). To measure store-operated calcium entry (SOCE), after the recording of the baseline T cells Ca<sup>++</sup> fluorescent for 1min, thapsigargin (TG) was added to induce store Ca<sup>++</sup> depletion, followed by the addition of Ca<sup>++</sup> 2μM in the extracellular medium to observe Ca<sup>++</sup> cellular entry.</p>
<p>Membrane potential was measured using FLIPR Membrane Potential Assay kit (Molecular devices) according to the manufacturer’s instructions. Specifically, T cells were loaded with FLIPR dye by adding an equal volume of FLIPR dye to the cells and incubated at 37°C for 30 minutes. Relative membrane potential was measured by detecting FLIPR dye incorporation using flow cytometry.</p>
</sec>
<sec id="s4l">
<title>Extracellular flux analysis (Seahorse assays)</title>
<p>Real-time measurements of extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were performed using an XFe-96 Bioanalyser (Agilent). T cells (2 × 10<sup>5</sup> cells per well; minimum of four wells per sample) were spun into previously poly-d-lysine-coated 96-well plates (Seahorse) in complete RPMI-1640 medium. ECAR was measured in RPMI medium in basal condition and in response to 25mM glucose, 1μM oligomycin, and 50mM of 2-DG (all from Sigma Aldrich). OCR was measured in RPMI medium supplemented with 25mM glucose, 2mM L-glutamine, and 1mM sodium pyruvate, under basal condition and in response to 1μM oligomycin, 1.5μM of carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone (FCCP) and 1μM of rotenone and antimycin (all from Sigma Aldrich).</p>
</sec>
<sec id="s4m">
<title>RNAseq and data analysis</title>
<p>RNASeq samples: 1. Anergic T cell analysis. Ctrl and Nrn1<sup>-/-</sup> OTII cells were sorted from the host mice (n=3 per group). 2. iTreg cell analysis. In vitro differentiated Nrn1<sup>-/-</sup> and ctrl iTreg cells were replated in resting condition (IL2 100u/ml) or stimulation condition (IL2 100u/ml and aCD3 5ug/ml). Cells were harvested 20 hr after replating for RNASeq analysis. 3. Effector T cells. Nrn1<sup>-/-</sup> and ctrl CD4 Tn cells were activated for 3 days (aCD3 5ug/ml, aCD28 2ug/ml), followed by replating in IL2 medium (100u/ml). Te cells were harvested two days after replating and subjected to RNASeq analysis.</p>
<p>RNA-sequencing analysis was performed by Admera Health (South Plainfield, NJ). Read quality was assessed with FastQC and aligned to the Mus Musculus genome (Ensembl GRCm38) using STAR aligner (version 2.6.0)(<xref ref-type="bibr" rid="c17">Dobin et al., 2013</xref>). Aligned reads were counted using HTSeq (version 0.9.0)(<xref ref-type="bibr" rid="c3">Anders et al., 2015</xref>), and the counts were loaded into R (The R Foundation). DESeq2 package (version 1.24.0)(<xref ref-type="bibr" rid="c40">Love et al., 2014</xref>) was used to normalize the raw counts. GSEA was performed using public gene sets (HALLMARK, and GO)(<xref ref-type="bibr" rid="c70">Subramanian et al., 2005</xref>). Cytoscape was used to display enriched gene sets cluster (<xref ref-type="bibr" rid="c64">Shannon et al., 2003</xref>).</p>
<p>Statistical analysis. All numerical data were processed using Graph Pad Prism 10. Data are expressed as the mean +/- the SEM, or as stated. Statistical comparisons were made using an unpaired student t-test or ANOVA with multiple comparison tests where 0.05 was considered significant, and a normal distribution was assumed. The p values are represented as follows: * p&lt;0.05; ** p&lt;0.01; *** p&lt;0.001, **** p&lt;0.0001.</p>
</sec>
</sec>
<sec id="d1e2230" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material id="d1e2354">
<label>Supplemental figure and Table</label>
<media xlink:href="supplements/578284_file02.pdf"/>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>This research is supported by grants from the Bloomberg-Kimmel Institute of JHU, the Melanoma Research Alliance, the National Institutes of Health (RO1AI099300 and RO1AI089830), and the Department of Defense (PC130767). JB’s research was supported by a Crohn’s and Colitis Foundation of America Research Fellowship, the Melanoma Research Foundation, and NCI grant P30CA016056.</p>
<p>We thank Dennis Gong for data processing and critical reading of the manuscript. We thank Dr. Elly Nedivi for providing polyclonal Nrn1 antibody and Dr. Fan Pan for reagent support. We thank Drs. Franck Housseau, Chien-Fu Hung for the constructive discussion of the project and the manuscript. We thank Drs. Hao Shi and Hongbo Chi for critical manuscript reading and helpful suggestions. We thank Dr. Rachel Helm for manuscript editing. We thank Drs. Richard L. Huganir, Bian Liu and Hana Goldschmidt for constructive discussion on Nrn1 and AMPAR connection.</p>
</ack>
<sec id="s5">
<title>Author contributions</title>
<p>H. Y. was involved in all aspects of this study, including planning and performing experiments, analyzing and interpreting data, and writing the manuscript. H. N. and J. B. were involved in performing experiments and data interpretation. P. V., Y. Z, and A. L. analyzed Nrn1 expression in Treg cells and carried out Treg suppression and functional assay. M. M. was involved in Nrn1 expression, Treg suppression assay, and manuscript writing. C. H. and C.D. conducted the anergy and Te cell differential gene expression study; Y.Z., J. F., and K. C. conducted an autoimmune inflammation study, and M. H. helped with mouse colony genotyping. X. Z. and Z. L. contributed to bioinformatic analysis. D.M. P. oversaw the project and was involved in data interpretation and manuscript preparation.</p>
</sec>
<sec id="s6">
<title>Competing interests</title>
<p>C.D. is a co-inventor on patents licensed from JHU to BMS and Janssen and is currently an employee of Janssen Research. D.M.P. is a consultant for Compugen, Shattuck Labs, WindMIL, Tempest, Immunai, Bristol-Myers Squibb, Amgen, Janssen, Astellas, Rockspring Capital, Immunomic, and Dracen; owns founders’ equity in ManaT Bio Inc., WindMIL, Trex, Jounce, Enara, Tizona, Tieza, and RAPT; and receives research funding from Compugen, Bristol-Myers Squibb, and Enara. All other authors do not have conflicting financial interests.</p>
</sec>
<sec id="s7">
<title>Data availability</title>
<p>The raw RNA sequencing data has been deposited under the GEO accession no. GSE121908 and GSE224083.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><mixed-citation publication-type="journal"><string-name><surname>Abdul Kadir</surname>, <given-names>L.</given-names></string-name>, <string-name><given-names>M.</given-names> <surname>Stacey</surname></string-name>, and <string-name><given-names>R.</given-names> <surname>Barrett-Jolley</surname></string-name>. <year>2018</year>. <article-title>Emerging Roles of the Membrane Potential: Action Beyond the Action Potential</article-title>. <source>Front Physiol</source> <volume>9</volume>:<fpage>1661</fpage>.</mixed-citation></ref>
<ref id="c2"><mixed-citation publication-type="journal"><string-name><surname>Adler</surname>, <given-names>A.J.</given-names></string-name>, <string-name><given-names>D.W.</given-names> <surname>Marsh</surname></string-name>, <string-name><given-names>G.S.</given-names> <surname>Yochum</surname></string-name>, <string-name><given-names>J.L.</given-names> <surname>Guzzo</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Nigam</surname></string-name>, <string-name><given-names>W.G.</given-names> <surname>Nelson</surname></string-name>, and <string-name><given-names>D.M.</given-names> <surname>Pardoll</surname></string-name>. <year>1998</year>. <article-title>CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells</article-title>. <source>The Journal of experimental medicine</source> <volume>187</volume>:<fpage>1555</fpage>–<lpage>1564</lpage>.</mixed-citation></ref>
<ref id="c3"><mixed-citation publication-type="journal"><string-name><surname>Anders</surname>, <given-names>S.</given-names></string-name>, <string-name><given-names>P.T.</given-names> <surname>Pyl</surname></string-name>, and <string-name><given-names>W.</given-names> <surname>Huber</surname></string-name>. <year>2015</year>. <article-title>HTSeq--a Python framework to work with high-throughput sequencing data</article-title>. <source>Bioinformatics</source> <volume>31</volume>:<fpage>166</fpage>–<lpage>169</lpage>.</mixed-citation></ref>
<ref id="c4"><mixed-citation publication-type="journal"><string-name><surname>Babst</surname>, <given-names>M</given-names></string-name>. <year>2020</year>. <article-title>Regulation of nutrient transporters by metabolic and environmental stresses</article-title>. <source>Curr Opin Cell Biol</source> <volume>65</volume>:<fpage>35</fpage>–<lpage>41</lpage>.</mixed-citation></ref>
<ref id="c5"><mixed-citation publication-type="journal"><string-name><surname>Blackiston</surname>, <given-names>D.J.</given-names></string-name>, <string-name><given-names>K.A.</given-names> <surname>McLaughlin</surname></string-name>, and <string-name><given-names>M.</given-names> <surname>Levin</surname></string-name>. <year>2009</year>. <article-title>Bioelectric controls of cell proliferation: ion channels, membrane voltage and the cell cycle</article-title>. <source>Cell Cycle</source> <volume>8</volume>:<fpage>3527</fpage>–<lpage>3536</lpage>.</mixed-citation></ref>
<ref id="c6"><mixed-citation publication-type="journal"><string-name><surname>Bohmwald</surname>, <given-names>K.</given-names></string-name>, <string-name><given-names>N.M.S.</given-names> <surname>Gálvez</surname></string-name>, <string-name><given-names>C.A.</given-names> <surname>Andrade</surname></string-name>, <string-name><given-names>V.P.</given-names> <surname>Mora</surname></string-name>, <string-name><given-names>J.T.</given-names> <surname>Muñoz</surname></string-name>, <string-name><given-names>P.A.</given-names> <surname>González</surname></string-name>, <string-name><given-names>C.A.</given-names> <surname>Riedel</surname></string-name>, and <string-name><given-names>A.M.</given-names> <surname>Kalergis</surname></string-name>. <year>2021</year>. <article-title>Modulation of Adaptive Immunity and Viral Infections by Ion Channels</article-title>. <source>Front Physiol</source> <volume>12</volume>:<fpage>736681</fpage>.</mixed-citation></ref>
<ref id="c7"><mixed-citation publication-type="journal"><string-name><surname>Bonnet</surname>, <given-names>C.S.</given-names></string-name>, <string-name><given-names>S.J.</given-names> <surname>Gilbert</surname></string-name>, <string-name><given-names>E.J.</given-names> <surname>Blain</surname></string-name>, <string-name><given-names>A.S.</given-names> <surname>Williams</surname></string-name>, and <string-name><given-names>D.J.</given-names> <surname>Mason</surname></string-name>. <year>2020</year>. <article-title>AMPA/kainate glutamate receptor antagonists prevent posttraumatic osteoarthritis</article-title>. <source>JCI insight</source> <volume>5</volume>:</mixed-citation></ref>
<ref id="c8"><mixed-citation publication-type="journal"><string-name><surname>Bonnet</surname>, <given-names>C.S.</given-names></string-name>, <string-name><given-names>A.S.</given-names> <surname>Williams</surname></string-name>, <string-name><given-names>S.J.</given-names> <surname>Gilbert</surname></string-name>, <string-name><given-names>A.K.</given-names> <surname>Harvey</surname></string-name>, <string-name><given-names>B.A.</given-names> <surname>Evans</surname></string-name>, and <string-name><given-names>D.J.</given-names> <surname>Mason</surname></string-name>. <year>2015</year>. <article-title>AMPA/kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis</article-title>. <source>Annals of the rheumatic diseases</source> <volume>74</volume>:<fpage>242</fpage>–<lpage>251</lpage>.</mixed-citation></ref>
<ref id="c9"><mixed-citation publication-type="journal"><string-name><surname>Buck</surname>, <given-names>M.D.</given-names></string-name>, <string-name><given-names>R.T.</given-names> <surname>Sowell</surname></string-name>, <string-name><given-names>S.M.</given-names> <surname>Kaech</surname></string-name>, and <string-name><given-names>E.L.</given-names> <surname>Pearce</surname></string-name>. <year>2017</year>. <article-title>Metabolic Instruction of Immunity</article-title>. <source>Cell</source> <volume>169</volume>:<fpage>570</fpage>–<lpage>586</lpage>.</mixed-citation></ref>
<ref id="c10"><mixed-citation publication-type="journal"><string-name><surname>Cantallops</surname>, <given-names>I.</given-names></string-name>, <string-name><given-names>K.</given-names> <surname>Haas</surname></string-name>, and <string-name><given-names>H.T.</given-names> <surname>Cline</surname></string-name>. <year>2000</year>. <article-title>Postsynaptic CPG15 promotes synaptic maturation and presynaptic axon arbor elaboration in vivo</article-title>. <source>Nature neuroscience</source> <volume>3</volume>:<fpage>1004</fpage>–<lpage>1011</lpage>.</mixed-citation></ref>
<ref id="c11"><mixed-citation publication-type="journal"><string-name><surname>Chapman</surname>, <given-names>N.M.</given-names></string-name>, and <string-name><given-names>H.</given-names> <surname>Chi</surname></string-name>. <year>2022</year>. <article-title>Metabolic adaptation of lymphocytes in immunity and disease</article-title>. <source>Immunity</source> <volume>55</volume>:<fpage>14</fpage>–<lpage>30</lpage>.</mixed-citation></ref>
<ref id="c12"><mixed-citation publication-type="journal"><string-name><surname>Chappert</surname>, <given-names>P.</given-names></string-name>, and <string-name><given-names>R.H.</given-names> <surname>Schwartz</surname></string-name>. <year>2010</year>. <article-title>Induction of T cell anergy: integration of environmental cues and infectious tolerance</article-title>. <source>Current opinion in immunology</source> <volume>22</volume>:<fpage>552</fpage>–<lpage>559</lpage>.</mixed-citation></ref>
<ref id="c13"><mixed-citation publication-type="journal"><string-name><surname>Chen</surname>, <given-names>T.C.</given-names></string-name>, <string-name><given-names>S.P.</given-names> <surname>Cobbold</surname></string-name>, <string-name><given-names>P.J.</given-names> <surname>Fairchild</surname></string-name>, and <string-name><given-names>H.</given-names> <surname>Waldmann</surname></string-name>. <year>2004</year>. <article-title>Generation of anergic and regulatory T cells following prolonged exposure to a harmless antigen</article-title>. <source>Journal of immunology (Baltimore, Md. : 1950)</source> <volume>172</volume>:<fpage>5900</fpage>-<lpage>5907</lpage>.</mixed-citation></ref>
<ref id="c14"><mixed-citation publication-type="journal"><string-name><surname>Choi</surname>, <given-names>S.</given-names></string-name>, and <string-name><given-names>R.H.</given-names> <surname>Schwartz</surname></string-name>. <year>2007</year>. <article-title>Molecular mechanisms for adaptive tolerance and other T cell anergy models</article-title>. <source>Seminars in immunology</source> <volume>19</volume>:<fpage>140</fpage>–<lpage>152</lpage>.</mixed-citation></ref>
<ref id="c15"><mixed-citation publication-type="journal"><string-name><surname>Cuenca</surname>, <given-names>A.</given-names></string-name>, <string-name><given-names>F.</given-names> <surname>Cheng</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Brayer</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Horna</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Gu</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Bien</surname></string-name>, <string-name><given-names>I.M.</given-names> <surname>Borrello</surname></string-name>, <string-name><given-names>H.I.</given-names> <surname>Levitsky</surname></string-name>, and <string-name><given-names>E.M.</given-names> <surname>Sotomayor</surname></string-name>. <year>2003</year>. <article-title>Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens</article-title>. <source>Cancer research</source> <volume>63</volume>:<fpage>9007</fpage>–<lpage>9015</lpage>.</mixed-citation></ref>
<ref id="c16"><mixed-citation publication-type="journal">DL, K.L.a.M. <year>2017</year>. <article-title>Relationship between CD4 Regulatory T Cells and Anergy In Vivo</article-title>. <source>Journal of immunology (Baltimore, Md. : 1950)</source> <volume>198</volume>:<fpage>2527</fpage>.</mixed-citation></ref>
<ref id="c17"><mixed-citation publication-type="journal"><string-name><surname>Dobin</surname>, <given-names>A.</given-names></string-name>, <string-name><given-names>C.A.</given-names> <surname>Davis</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Schlesinger</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Drenkow</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Zaleski</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Jha</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Batut</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Chaisson</surname></string-name>, and <string-name><given-names>T.R.</given-names> <surname>Gingeras</surname></string-name>. <year>2013</year>. <article-title>STAR: ultrafast universal RNA-seq aligner</article-title>. <source>Bioinformatics</source> <volume>29</volume>:<fpage>15</fpage>–<lpage>21</lpage>.</mixed-citation></ref>
<ref id="c18"><mixed-citation publication-type="journal"><string-name><surname>Dvorak</surname>, <given-names>V.</given-names></string-name>, <string-name><given-names>T.</given-names> <surname>Wiedmer</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Ingles-Prieto</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Altermatt</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Batoulis</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Bärenz</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Bender</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Digles</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Dürrenberger</surname></string-name>, <string-name><given-names>L.H.</given-names> <surname>Heitman</surname></string-name>, <string-name><given-names>I.J.</given-names> <surname>AP</surname></string-name>, <string-name><given-names>D.B.</given-names> <surname>Kell</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Kickinger</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Körzö</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Leippe</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Licher</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Manolova</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Rizzetto</surname></string-name>, <string-name><given-names>F.</given-names> <surname>Sassone</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Scarabottolo</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Schlessinger</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Schneider</surname></string-name>, <string-name><given-names>H.J.</given-names> <surname>Sijben</surname></string-name>, <string-name><given-names>A.L.</given-names> <surname>Steck</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Sundström</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Tremolada</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Wilhelm</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Wright Muelas</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Zindel</surname></string-name>, <string-name><given-names>C.M.</given-names> <surname>Steppan</surname></string-name>, and <string-name><given-names>G.</given-names> <surname>Superti-Furga</surname></string-name>. <year>2021</year>. <article-title>An Overview of Cell-Based Assay Platforms for the Solute Carrier Family of Transporters</article-title>. <source>Frontiers in pharmacology</source> <volume>12</volume>:<fpage>722889</fpage>.</mixed-citation></ref>
<ref id="c19"><mixed-citation publication-type="journal"><string-name><surname>ElTanbouly</surname>, <given-names>M.A.</given-names></string-name>, and <string-name><given-names>R.J.</given-names> <surname>Noelle</surname></string-name>. <year>2021</year>. <article-title>Rethinking peripheral T cell tolerance: checkpoints across a T cell’s journey</article-title>. <source>Nat Rev Immunol</source> <volume>21</volume>:<fpage>257</fpage>–<lpage>267</lpage>.</mixed-citation></ref>
<ref id="c20"><mixed-citation publication-type="journal"><string-name><surname>Emmons-Bell</surname>, <given-names>M.</given-names></string-name>, and <string-name><given-names>I.K.</given-names> <surname>Hariharan</surname></string-name>. <year>2021</year>. <article-title>Membrane potential regulates Hedgehog signalling in the Drosophila wing imaginal disc</article-title>. <source>EMBO reports</source> <volume>22</volume>:<fpage>e51861</fpage>.</mixed-citation></ref>
<ref id="c21"><mixed-citation publication-type="journal"><string-name><surname>Feng</surname>, <given-names>Y.</given-names></string-name>, <string-name><given-names>A.</given-names> <surname>Arvey</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Chinen</surname></string-name>, <string-name><given-names>J.</given-names> <surname>van der Veeken</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Gasteiger</surname></string-name>, and <string-name><given-names>A.Y.</given-names> <surname>Rudensky</surname></string-name>. <year>2014</year>. <article-title>Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus</article-title>. <source>Cell</source> <volume>158</volume>:<fpage>749</fpage>–<lpage>763</lpage>.</mixed-citation></ref>
<ref id="c22"><mixed-citation publication-type="journal"><string-name><surname>Floess</surname>, <given-names>S.</given-names></string-name>, <string-name><given-names>J.</given-names> <surname>Freyer</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Siewert</surname></string-name>, <string-name><given-names>U.</given-names> <surname>Baron</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Olek</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Polansky</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Schlawe</surname></string-name>, <string-name><given-names>H.D.</given-names> <surname>Chang</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Bopp</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Schmitt</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Klein-Hessling</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Serfling</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Hamann</surname></string-name>, and <string-name><given-names>J.</given-names> <surname>Huehn</surname></string-name>. <year>2007</year>. <article-title>Epigenetic control of the foxp3 locus in regulatory T cells</article-title>. <source>PLoS biology</source> <volume>5</volume>:<fpage>e38</fpage>.</mixed-citation></ref>
<ref id="c23"><mixed-citation publication-type="journal"><string-name><surname>Fujino</surname>, <given-names>T.</given-names></string-name>, <string-name><given-names>J.H.</given-names> <surname>Leslie</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Eavri</surname></string-name>, <string-name><given-names>J.L.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>W.C.</given-names> <surname>Lin</surname></string-name>, <string-name><given-names>G.H.</given-names> <surname>Flanders</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Borok</surname></string-name>, <string-name><given-names>T.L.</given-names> <surname>Horvath</surname></string-name>, and <string-name><given-names>E.</given-names> <surname>Nedivi</surname></string-name>. <year>2011</year>. <article-title>CPG15 regulates synapse stability in the developing and adult brain</article-title>. <source>Genes &amp; development</source> <volume>25</volume>:<fpage>2674</fpage>–<lpage>2685</lpage>.</mixed-citation></ref>
<ref id="c24"><mixed-citation publication-type="journal"><string-name><surname>Geltink</surname>, <given-names>R.I.K.</given-names></string-name>, <string-name><given-names>R.L.</given-names> <surname>Kyle</surname></string-name>, and <string-name><given-names>E.L.</given-names> <surname>Pearce</surname></string-name>. <year>2018</year>. <article-title>Unraveling the Complex Interplay Between T Cell Metabolism and Function</article-title>. <source>Annual review of immunology</source> <volume>36</volume>:<fpage>461</fpage>–<lpage>488</lpage>.</mixed-citation></ref>
<ref id="c25"><mixed-citation publication-type="journal"><string-name><surname>Gonzalez-Figueroa</surname>, <given-names>P.</given-names></string-name>, <string-name><given-names>J.A.</given-names> <surname>Roco</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Papa</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Núñez Villacís</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Stanley</surname></string-name>, <string-name><given-names>M.A.</given-names> <surname>Linterman</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Dent</surname></string-name>, <string-name><given-names>P.F.</given-names> <surname>Canete</surname></string-name>, and <string-name><given-names>C.G.</given-names> <surname>Vinuesa</surname></string-name>. <year>2021</year>. <article-title>Follicular regulatory T cells produce neuritin to regulate B cells</article-title>. <source>Cell</source></mixed-citation></ref>
<ref id="c26"><mixed-citation publication-type="journal"><string-name><surname>Hamill</surname>, <given-names>M.J.</given-names></string-name>, <string-name><given-names>R.</given-names> <surname>Afeyan</surname></string-name>, <string-name><given-names>M.V.</given-names> <surname>Chakravarthy</surname></string-name>, and <string-name><given-names>T.</given-names> <surname>Tramontin</surname></string-name>. <year>2020</year>. <article-title>Endogenous Metabolic Modulators: Emerging Therapeutic Potential of Amino Acids</article-title>. <source>iScience</source> <volume>23</volume>:<fpage>101628</fpage>.</mixed-citation></ref>
<ref id="c27"><mixed-citation publication-type="journal"><string-name><surname>Huang</surname>, <given-names>C.T.</given-names></string-name>, <string-name><given-names>D.L.</given-names> <surname>Huso</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Lu</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>E.P.</given-names> <surname>Kennedy</surname></string-name>, <string-name><given-names>C.G.</given-names> <surname>Drake</surname></string-name>, <string-name><given-names>D.J.</given-names> <surname>Morgan</surname></string-name>, <string-name><given-names>L.A.</given-names> <surname>Sherman</surname></string-name>, <string-name><given-names>A.D.</given-names> <surname>Higgins</surname></string-name>, <string-name><given-names>D.M.</given-names> <surname>Pardoll</surname></string-name>, and <string-name><given-names>A.J.</given-names> <surname>Adler</surname></string-name>. <year>2003</year>. <article-title>CD4+ T cells pass through an effector phase during the process of in vivo tolerance induction</article-title>. <source>Journal of immunology (Baltimore, Md. : 1950)</source> <volume>170</volume>:<fpage>3945</fpage>–<lpage>3953</lpage>.</mixed-citation></ref>
<ref id="c28"><mixed-citation publication-type="journal"><string-name><surname>Huang</surname>, <given-names>C.T.</given-names></string-name>, <string-name><given-names>C.J.</given-names> <surname>Workman</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Flies</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Pan</surname></string-name>, <string-name><given-names>A.L.</given-names> <surname>Marson</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>E.L.</given-names> <surname>Hipkiss</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Ravi</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Kowalski</surname></string-name>, <string-name><given-names>H.I.</given-names> <surname>Levitsky</surname></string-name>, <string-name><given-names>J.D.</given-names> <surname>Powell</surname></string-name>, <string-name><given-names>D.M.</given-names> <surname>Pardoll</surname></string-name>, <string-name><given-names>C.G.</given-names> <surname>Drake</surname></string-name>, and <string-name><given-names>D.A.</given-names> <surname>Vignali</surname></string-name>. <year>2004</year>. <article-title>Role of LAG-3 in regulatory T cells</article-title>. <source>Immunity</source> <volume>21</volume>:<fpage>503</fpage>–<lpage>513</lpage>.</mixed-citation></ref>
<ref id="c29"><mixed-citation publication-type="journal"><string-name><surname>Javaherian</surname>, <given-names>A.</given-names></string-name>, and <string-name><given-names>H.T.</given-names> <surname>Cline</surname></string-name>. <year>2005</year>. <article-title>Coordinated motor neuron axon growth and neuromuscular synaptogenesis are promoted by CPG15 in vivo</article-title>. <source>Neuron</source> <volume>45</volume>:<fpage>505</fpage>–<lpage>512</lpage>.</mixed-citation></ref>
<ref id="c30"><mixed-citation publication-type="journal"><string-name><surname>Joesch</surname>, <given-names>C.</given-names></string-name>, <string-name><given-names>E.</given-names> <surname>Guevarra</surname></string-name>, <string-name><given-names>S.P.</given-names> <surname>Parel</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Bergner</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Zbinden</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Konrad</surname></string-name>, and <string-name><given-names>H.</given-names> <surname>Albrecht</surname></string-name>. <year>2008</year>. <article-title>Use of FLIPR membrane potential dyes for validation of high-throughput screening with the FLIPR and microARCS technologies: identification of ion channel modulators acting on the GABA(A) receptor</article-title>. <source>J Biomol Screen</source> <volume>13</volume>:<fpage>218</fpage>–<lpage>228</lpage>.</mixed-citation></ref>
<ref id="c31"><mixed-citation publication-type="journal"><string-name><surname>Kalekar</surname>, <given-names>L.A.</given-names></string-name>, <string-name><given-names>S.E.</given-names> <surname>Schmiel</surname></string-name>, <string-name><given-names>S.L.</given-names> <surname>Nandiwada</surname></string-name>, <string-name><given-names>W.Y.</given-names> <surname>Lam</surname></string-name>, <string-name><given-names>L.O.</given-names> <surname>Barsness</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>G.L.</given-names> <surname>Stritesky</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Malhotra</surname></string-name>, <string-name><given-names>K.E.</given-names> <surname>Pauken</surname></string-name>, <string-name><given-names>J.L.</given-names> <surname>Linehan</surname></string-name>, <string-name><given-names>M.G.</given-names> <surname>O’Sullivan</surname></string-name>, <string-name><given-names>B.T.</given-names> <surname>Fife</surname></string-name>, <string-name><given-names>K.A.</given-names> <surname>Hogquist</surname></string-name>, <string-name><given-names>M.K.</given-names> <surname>Jenkins</surname></string-name>, and <string-name><given-names>D.L.</given-names> <surname>Mueller</surname></string-name>. <year>2016</year>. <article-title>CD4(+) T cell anergy prevents autoimmunity and generates regulatory T cell precursors</article-title>. <source>Nature immunology</source> <volume>17</volume>:<fpage>304</fpage>–<lpage>314</lpage>.</mixed-citation></ref>
<ref id="c32"><mixed-citation publication-type="journal"><string-name><surname>Kiefer</surname>, <given-names>H.</given-names></string-name>, <string-name><given-names>A.J.</given-names> <surname>Blume</surname></string-name>, and <string-name><given-names>H.R.</given-names> <surname>Kaback</surname></string-name>. <year>1980</year>. <article-title>Membrane potential changes during mitogenic stimulation of mouse spleen lymphocytes</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <volume>77</volume>:<fpage>2200</fpage>–<lpage>2204</lpage>.</mixed-citation></ref>
<ref id="c33"><mixed-citation publication-type="journal"><string-name><surname>Kim</surname>, <given-names>J.M.</given-names></string-name>, <string-name><given-names>J.P.</given-names> <surname>Rasmussen</surname></string-name>, and <string-name><given-names>A.Y.</given-names> <surname>Rudensky</surname></string-name>. <year>2007</year>. <article-title>Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice</article-title>. <source>Nature immunology</source> <volume>8</volume>:<fpage>191</fpage>–<lpage>197</lpage>.</mixed-citation></ref>
<ref id="c34"><mixed-citation publication-type="journal"><string-name><surname>Kuczma</surname>, <given-names>M.P.</given-names></string-name>, <string-name><given-names>E.A.</given-names> <surname>Szurek</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Cebula</surname></string-name>, <string-name><given-names>V.L.</given-names> <surname>Ngo</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Pietrzak</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Kraj</surname></string-name>, <string-name><given-names>T.L.</given-names> <surname>Denning</surname></string-name>, and <string-name><given-names>L.</given-names> <surname>Ignatowicz</surname></string-name>. <year>2021</year>. <article-title>Self and microbiota-derived epitopes induce CD4(+) T cell anergy and conversion into CD4(+)Foxp3(+) regulatory cells</article-title>. <source>Mucosal Immunol</source> <volume>14</volume>:<fpage>443</fpage>–<lpage>454</lpage>.</mixed-citation></ref>
<ref id="c35"><mixed-citation publication-type="journal"><string-name><surname>Levin</surname>, <given-names>M</given-names></string-name>. <year>2021</year>. <article-title>Bioelectric signaling: Reprogrammable circuits underlying embryogenesis, regeneration, and cancer</article-title>. <source>Cell</source> <volume>184</volume>:<fpage>1971</fpage>–<lpage>1989</lpage>.</mixed-citation></ref>
<ref id="c36"><mixed-citation publication-type="journal"><string-name><surname>Li</surname>, <given-names>X.</given-names></string-name>, <string-name><given-names>Y.</given-names> <surname>Liang</surname></string-name>, <string-name><given-names>M.</given-names> <surname>LeBlanc</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Benner</surname></string-name>, and <string-name><given-names>Y.</given-names> <surname>Zheng</surname></string-name>. <year>2014</year>. <article-title>Function of a Foxp3 cis-element in protecting regulatory T cell identity</article-title>. <source>Cell</source> <volume>158</volume>:<fpage>734</fpage>–<lpage>748</lpage>.</mixed-citation></ref>
<ref id="c37"><mixed-citation publication-type="journal"><string-name><surname>Lim</surname>, <given-names>D.G.</given-names></string-name>, <string-name><given-names>Y.H.</given-names> <surname>Park</surname></string-name>, <string-name><given-names>S.E.</given-names> <surname>Kim</surname></string-name>, <string-name><given-names>S.H.</given-names> <surname>Jeong</surname></string-name>, and <string-name><given-names>S.C.</given-names> <surname>Kim</surname></string-name>. <year>2013</year>. <article-title>Diagnostic value of tolerance-related gene expression measured in the recipient alloantigen-reactive T cell fraction</article-title>. <source>Clinical immunology (Orlando, Fla.)</source> <volume>148</volume>:<fpage>219</fpage>–<lpage>226</lpage>.</mixed-citation></ref>
<ref id="c38"><mixed-citation publication-type="journal"><string-name><surname>Liu</surname>, <given-names>G.Y.</given-names></string-name>, and <string-name><given-names>D.M.</given-names> <surname>Sabatini</surname></string-name>. <year>2020</year>. <article-title>mTOR at the nexus of nutrition, growth, ageing and disease</article-title>. <source>Nat Rev Mol Cell Biol</source> <volume>21</volume>:<fpage>183</fpage>–<lpage>203</lpage>.</mixed-citation></ref>
<ref id="c39"><mixed-citation publication-type="journal"><string-name><surname>Long</surname>, <given-names>L.</given-names></string-name>, <string-name><given-names>J.</given-names> <surname>Wei</surname></string-name>, <string-name><given-names>S.A.</given-names> <surname>Lim</surname></string-name>, <string-name><given-names>J.L.</given-names> <surname>Raynor</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Shi</surname></string-name>, <string-name><given-names>J.P.</given-names> <surname>Connelly</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Guy</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Xie</surname></string-name>, <string-name><given-names>N.M.</given-names> <surname>Chapman</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Fu</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Huang</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Su</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Saravia</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Risch</surname></string-name>, <string-name><given-names>Y.D.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Niu</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Dhungana</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Kc</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Zhou</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Vogel</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Yu</surname></string-name>, <string-name><given-names>S.M.</given-names> <surname>Pruett-Miller</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Peng</surname></string-name>, and <string-name><given-names>H.</given-names> <surname>Chi</surname></string-name>. <year>2021</year>. <article-title>CRISPR screens unveil signal hubs for nutrient licensing of T cell immunity</article-title>. <source>Nature</source> <volume>600</volume>:<fpage>308</fpage>–<lpage>313</lpage>.</mixed-citation></ref>
<ref id="c40"><mixed-citation publication-type="journal"><string-name><surname>Love</surname>, <given-names>M.I.</given-names></string-name>, <string-name><given-names>W.</given-names> <surname>Huber</surname></string-name>, and <string-name><given-names>S.</given-names> <surname>Anders</surname></string-name>. <year>2014</year>. <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome biology</source> <volume>15</volume>:<fpage>550</fpage>.</mixed-citation></ref>
<ref id="c41"><mixed-citation publication-type="journal"><string-name><surname>Ma</surname>, <given-names>Y.</given-names></string-name>, <string-name><given-names>K.</given-names> <surname>Poole</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Goyette</surname></string-name>, and <string-name><given-names>K.</given-names> <surname>Gaus</surname></string-name>. <year>2017</year>. <article-title>Introducing Membrane Charge and Membrane Potential to T Cell Signaling</article-title>. <source>Frontiers in immunology</source> <volume>8</volume>:<fpage>1513</fpage>.</mixed-citation></ref>
<ref id="c42"><mixed-citation publication-type="journal"><string-name><surname>Martinez</surname>, <given-names>R.J.</given-names></string-name>, <string-name><given-names>N.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>S.R.</given-names> <surname>Thomas</surname></string-name>, <string-name><given-names>S.L.</given-names> <surname>Nandiwada</surname></string-name>, <string-name><given-names>M.K.</given-names> <surname>Jenkins</surname></string-name>, <string-name><given-names>B.A.</given-names> <surname>Binstadt</surname></string-name>, and <string-name><given-names>D.L.</given-names> <surname>Mueller</surname></string-name>. <year>2012</year>. <article-title>Arthritogenic self-reactive CD4+ T cells acquire an FR4hiCD73hi anergic state in the presence of Foxp3+ regulatory T cells</article-title>. <source>Journal of immunology (Baltimore, Md. : 1950)</source> <volume>188</volume>:<fpage>170</fpage>–<lpage>181</lpage>.</mixed-citation></ref>
<ref id="c43"><mixed-citation publication-type="journal"><string-name><surname>McNearney</surname>, <given-names>T.</given-names></string-name>, <string-name><given-names>B.A.</given-names> <surname>Baethge</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Cao</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Alam</surname></string-name>, <string-name><given-names>J.R.</given-names> <surname>Lisse</surname></string-name>, and <string-name><given-names>K.N.</given-names> <surname>Westlund</surname></string-name>. <year>2004</year>. <article-title>Excitatory amino acids, TNF-alpha, and chemokine levels in synovial fluids of patients with active arthropathies</article-title>. <source>Clinical and experimental immunology</source> <volume>137</volume>:<fpage>621</fpage>–<lpage>627</lpage>.</mixed-citation></ref>
<ref id="c44"><mixed-citation publication-type="journal"><string-name><surname>Mercadante</surname>, <given-names>E.R.</given-names></string-name>, and <string-name><given-names>U.M.</given-names> <surname>Lorenz</surname></string-name>. <year>2016</year>. <article-title>Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression</article-title>. <source>Frontiers in immunology</source> <volume>7</volume>:<fpage>193</fpage>.</mixed-citation></ref>
<ref id="c45"><mixed-citation publication-type="journal"><string-name><surname>Miller</surname>, <given-names>S.D.</given-names></string-name>, <string-name><given-names>W.J.</given-names> <surname>Karpus</surname></string-name>, and <string-name><given-names>T.S.</given-names> <surname>Davidson</surname></string-name>. <year>2007</year>. <article-title>Experimental Autoimmune Encephalomyelitis in the Mouse</article-title>. <source>Current protocols in immunology CHAPTER:Unit</source>-<volume>15</volume> <fpage>11</fpage>.</mixed-citation></ref>
<ref id="c46"><mixed-citation publication-type="journal"><string-name><surname>Monroe</surname>, <given-names>J.G.</given-names></string-name>, and <string-name><given-names>J.C.</given-names> <surname>Cambier</surname></string-name>. <year>1983</year>. <article-title>B cell activation. I. Anti-immunoglobulin-induced receptor cross-linking results in a decrease in the plasma membrane potential of murine B lymphocytes</article-title>. <source>The Journal of experimental medicine</source> <volume>157</volume>:<fpage>2073</fpage>–<lpage>2086</lpage>.</mixed-citation></ref>
<ref id="c47"><mixed-citation publication-type="journal"><string-name><surname>Nedivi</surname>, <given-names>E.</given-names></string-name>, <string-name><given-names>G.Y.</given-names> <surname>Wu</surname></string-name>, and <string-name><given-names>H.T.</given-names> <surname>Cline</surname></string-name>. <year>1998</year>. <article-title>Promotion of dendritic growth by CPG15, an activity-induced signaling molecule</article-title>. <source>Science (New York, N.Y.)</source> <volume>281</volume>:<fpage>1863</fpage>–<lpage>1866</lpage>.</mixed-citation></ref>
<ref id="c48"><mixed-citation publication-type="journal"><string-name><surname>Nik</surname>, <given-names>A.M.</given-names></string-name>, <string-name><given-names>B.</given-names> <surname>Pressly</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Singh</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Antrobus</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Hulsizer</surname></string-name>, <string-name><given-names>M.A.</given-names> <surname>Rogawski</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Wulff</surname></string-name>, and <string-name><given-names>I.N.</given-names> <surname>Pessah</surname></string-name>. <year>2017</year>. <article-title>Rapid Throughput Analysis of GABA(A) Receptor Subtype Modulators and Blockers Using DiSBAC(1)(3) Membrane Potential Red Dye</article-title>. <source>Mol Pharmacol</source> <volume>92</volume>:<fpage>88</fpage>–<lpage>99</lpage>.</mixed-citation></ref>
<ref id="c49"><mixed-citation publication-type="journal"><string-name><surname>Nystrom</surname>, <given-names>S.N.</given-names></string-name>, <string-name><given-names>D.</given-names> <surname>Bourges</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Garry</surname></string-name>, <string-name><given-names>E.M.</given-names> <surname>Ross</surname></string-name>, <string-name><given-names>I.R.</given-names> <surname>van Driel</surname></string-name>, and <string-name><given-names>P.A.</given-names> <surname>Gleeson</surname></string-name>. <year>2014</year>. <article-title>Transient Treg-cell depletion in adult mice results in persistent self-reactive CD4(+) T-cell responses</article-title>. <source>European journal of immunology</source> <volume>44</volume>:<fpage>3621</fpage>–<lpage>3631</lpage>.</mixed-citation></ref>
<ref id="c50"><mixed-citation publication-type="journal"><string-name><surname>Olenchock</surname>, <given-names>B.A.</given-names></string-name>, <string-name><given-names>J.C.</given-names> <surname>Rathmell</surname></string-name>, and <string-name><given-names>M.G.</given-names> <surname>Vander Heiden</surname></string-name>. <year>2017</year>. <article-title>Biochemical Underpinnings of Immune Cell Metabolic Phenotypes</article-title>. <source>Immunity</source> <volume>46</volume>:<fpage>703</fpage>–<lpage>713</lpage>.</mixed-citation></ref>
<ref id="c51"><mixed-citation publication-type="journal"><string-name><surname>Opejin</surname>, <given-names>A.</given-names></string-name>, <string-name><given-names>A.</given-names> <surname>Surnov</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Misulovin</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Pherson</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Gross</surname></string-name>, <string-name><given-names>C.A.</given-names> <surname>Iberg</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Fallahee</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Bourque</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Dorsett</surname></string-name>, and <string-name><given-names>D.</given-names> <surname>Hawiger</surname></string-name>. <year>2020</year>. <article-title>A Two-Step Process of Effector Programming Governs CD4(+) T Cell Fate Determination Induced by Antigenic Activation in the Steady State</article-title>. <source>Cell reports</source> <volume>33</volume>:<fpage>108424</fpage>.</mixed-citation></ref>
<ref id="c52"><mixed-citation publication-type="journal"><string-name><surname>Pandya</surname>, <given-names>N.J.</given-names></string-name>, <string-name><given-names>C.</given-names> <surname>Seeger</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Babai</surname></string-name>, <string-name><given-names>M.A.</given-names> <surname>Gonzalez-Lozano</surname></string-name>, <string-name><given-names>V.</given-names> <surname>Mack</surname></string-name>, <string-name><given-names>J.C.</given-names> <surname>Lodder</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Gouwenberg</surname></string-name>, <string-name><given-names>H.D.</given-names> <surname>Mansvelder</surname></string-name>, <string-name><given-names>U.H.</given-names> <surname>Danielson</surname></string-name>, <string-name><given-names>K.W.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Heine</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Spijker</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Frischknecht</surname></string-name>, and <string-name><given-names>A.B.</given-names> <surname>Smit</surname></string-name>. <year>2018</year>. <article-title>Noelin1 Affects Lateral Mobility of Synaptic AMPA Receptors</article-title>. <source>Cell reports</source> <volume>24</volume>:<fpage>1218</fpage>–<lpage>1230</lpage>.</mixed-citation></ref>
<ref id="c53"><mixed-citation publication-type="journal"><string-name><surname>Peng</surname>, <given-names>M.</given-names></string-name>, and <string-name><given-names>M.O.</given-names> <surname>Li</surname></string-name>. <year>2023</year>. <article-title>Metabolism along the life journey of T cells</article-title>. <source>Life Metab</source> <volume>2</volume>:</mixed-citation></ref>
<ref id="c54"><mixed-citation publication-type="journal"><string-name><surname>Plitas</surname>, <given-names>G.</given-names></string-name>, <string-name><given-names>C.</given-names> <surname>Konopacki</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>P.D.</given-names> <surname>Bos</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Morrow</surname></string-name>, <string-name><given-names>E.V.</given-names> <surname>Putintseva</surname></string-name>, <string-name><given-names>D.M.</given-names> <surname>Chudakov</surname></string-name>, and <string-name><given-names>A.Y.</given-names> <surname>Rudensky</surname></string-name>. <year>2016</year>. <article-title>Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer</article-title>. <source>Immunity</source> <volume>45</volume>:<fpage>1122</fpage>–<lpage>1134</lpage>.</mixed-citation></ref>
<ref id="c55"><mixed-citation publication-type="journal"><string-name><surname>Putz</surname>, <given-names>U.</given-names></string-name>, <string-name><given-names>C.</given-names> <surname>Harwell</surname></string-name>, and <string-name><given-names>E.</given-names> <surname>Nedivi</surname></string-name>. <year>2005</year>. <article-title>Soluble CPG15 expressed during early development rescues cortical progenitors from apoptosis</article-title>. <source>Nature neuroscience</source> <volume>8</volume>:<fpage>322</fpage>–<lpage>331</lpage>.</mixed-citation></ref>
<ref id="c56"><mixed-citation publication-type="journal"><string-name><surname>Ramirez</surname>, <given-names>G.A.</given-names></string-name>, <string-name><given-names>L.A.</given-names> <surname>Coletto</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Sciorati</surname></string-name>, <string-name><given-names>E.P.</given-names> <surname>Bozzolo</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Manunta</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Rovere-Querini</surname></string-name>, and <string-name><given-names>A.A.</given-names> <surname>Manfredi</surname></string-name>. <year>2018</year>. <article-title>Ion Channels and Transporters in Inflammation: Special Focus on TRP Channels and TRPC6</article-title>. <source>Cells</source> <volume>7</volume>:</mixed-citation></ref>
<ref id="c57"><mixed-citation publication-type="journal"><string-name><surname>Safford</surname>, <given-names>M.</given-names></string-name>, <string-name><given-names>S.</given-names> <surname>Collins</surname></string-name>, <string-name><given-names>M.A.</given-names> <surname>Lutz</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Allen</surname></string-name>, <string-name><given-names>C.T.</given-names> <surname>Huang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Kowalski</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Blackford</surname></string-name>, <string-name><given-names>M.R.</given-names> <surname>Horton</surname></string-name>, <string-name><given-names>C.</given-names> <surname>Drake</surname></string-name>, <string-name><given-names>R.H.</given-names> <surname>Schwartz</surname></string-name>, and <string-name><given-names>J.D.</given-names> <surname>Powell</surname></string-name>. <year>2005</year>. <article-title>Egr-2 and Egr-3 are negative regulators of T cell activation</article-title>. <source>Nature immunology</source> <volume>6</volume>:<fpage>472</fpage>–<lpage>480</lpage>.</mixed-citation></ref>
<ref id="c58"><mixed-citation publication-type="journal"><string-name><surname>Salmond</surname>, <given-names>R.J</given-names></string-name>. <year>2018</year>. <article-title>mTOR Regulation of Glycolytic Metabolism in T Cells</article-title>. <source>Frontiers in cell and developmental biology</source> <volume>6</volume>:<fpage>122</fpage>.</mixed-citation></ref>
<ref id="c59"><mixed-citation publication-type="journal"><string-name><surname>Saravia</surname>, <given-names>J.</given-names></string-name>, <string-name><given-names>J.L.</given-names> <surname>Raynor</surname></string-name>, <string-name><given-names>N.M.</given-names> <surname>Chapman</surname></string-name>, <string-name><given-names>S.A.</given-names> <surname>Lim</surname></string-name>, and <string-name><given-names>H.</given-names> <surname>Chi</surname></string-name>. <year>2020</year>. <article-title>Signaling networks in immunometabolism</article-title>. <source>Cell research</source> <volume>30</volume>:<fpage>328</fpage>–<lpage>342</lpage>.</mixed-citation></ref>
<ref id="c60"><mixed-citation publication-type="journal"><string-name><surname>Sarchielli</surname>, <given-names>P.</given-names></string-name>, <string-name><given-names>M.</given-names> <surname>Di Filippo</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Candeliere</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Chiasserini</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Mattioni</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Tenaglia</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Bonucci</surname></string-name>, and <string-name><given-names>P.</given-names> <surname>Calabresi</surname></string-name>. <year>2007</year>. <article-title>Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients</article-title>. <source>Journal of neuroimmunology</source> <volume>188</volume>:<fpage>146</fpage>–<lpage>158</lpage>.</mixed-citation></ref>
<ref id="c61"><mixed-citation publication-type="journal"><string-name><surname>Schietinger</surname>, <given-names>A.</given-names></string-name>, <string-name><given-names>J.J.</given-names> <surname>Delrow</surname></string-name>, <string-name><given-names>R.S.</given-names> <surname>Basom</surname></string-name>, <string-name><given-names>J.N.</given-names> <surname>Blattman</surname></string-name>, and <string-name><given-names>P.D.</given-names> <surname>Greenberg</surname></string-name>. <year>2012</year>. <article-title>Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state</article-title>. <source>Science (New York, N.Y.)</source> <volume>335</volume>:<fpage>723</fpage>–<lpage>727</lpage>.</mixed-citation></ref>
<ref id="c62"><mixed-citation publication-type="journal"><string-name><surname>Schietinger</surname>, <given-names>A.</given-names></string-name>, <string-name><given-names>M.</given-names> <surname>Philip</surname></string-name>, <string-name><given-names>V.E.</given-names> <surname>Krisnawan</surname></string-name>, <string-name><given-names>E.Y.</given-names> <surname>Chiu</surname></string-name>, <string-name><given-names>J.J.</given-names> <surname>Delrow</surname></string-name>, <string-name><given-names>R.S.</given-names> <surname>Basom</surname></string-name>, <string-name><given-names>P.</given-names> <surname>Lauer</surname></string-name>, <string-name><given-names>D.G.</given-names> <surname>Brockstedt</surname></string-name>, <string-name><given-names>S.E.</given-names> <surname>Knoblaugh</surname></string-name>, <string-name><given-names>G.J.</given-names> <surname>Hammerling</surname></string-name>, <string-name><given-names>T.D.</given-names> <surname>Schell</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Garbi</surname></string-name>, and <string-name><given-names>P.D.</given-names> <surname>Greenberg</surname></string-name>. <year>2016</year>. <article-title>Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis</article-title>. <source>Immunity</source> <volume>45</volume>:<fpage>389</fpage>–<lpage>401</lpage>.</mixed-citation></ref>
<ref id="c63"><mixed-citation publication-type="journal"><string-name><surname>Schwenk</surname>, <given-names>J.</given-names></string-name>, <string-name><given-names>N.</given-names> <surname>Harmel</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Brechet</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Zolles</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Berkefeld</surname></string-name>, <string-name><given-names>C.S.</given-names> <surname>Muller</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Bildl</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Baehrens</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Huber</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Kulik</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Klocker</surname></string-name>, <string-name><given-names>U.</given-names> <surname>Schulte</surname></string-name>, and <string-name><given-names>B.</given-names> <surname>Fakler</surname></string-name>. <year>2012</year>. <article-title>High-resolution proteomics unravel architecture and molecular diversity of native AMPA receptor complexes</article-title>. <source>Neuron</source> <volume>74</volume>:<fpage>621</fpage>–<lpage>633</lpage>.</mixed-citation></ref>
<ref id="c64"><mixed-citation publication-type="journal"><string-name><surname>Shannon</surname>, <given-names>P.</given-names></string-name>, <string-name><given-names>A.</given-names> <surname>Markiel</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Ozier</surname></string-name>, <string-name><given-names>N.S.</given-names> <surname>Baliga</surname></string-name>, <string-name><given-names>J.T.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Ramage</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Amin</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Schwikowski</surname></string-name>, and <string-name><given-names>T.</given-names> <surname>Ideker</surname></string-name>. <year>2003</year>. <article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title>. <source>Genome Res</source> <volume>13</volume>:<fpage>2498</fpage>–<lpage>2504</lpage>.</mixed-citation></ref>
<ref id="c65"><mixed-citation publication-type="journal"><string-name><surname>Shimada</surname>, <given-names>T.</given-names></string-name>, <string-name><given-names>T.</given-names> <surname>Yoshida</surname></string-name>, and <string-name><given-names>K.</given-names> <surname>Yamagata</surname></string-name>. <year>2016</year>. <article-title>Neuritin Mediates Activity-Dependent Axonal Branch Formation in Part via FGF Signaling</article-title>. <source>The Journal of neuroscience : the official journal of the Society for Neuroscience</source> <volume>36</volume>:<fpage>4534</fpage>–<lpage>4548</lpage>.</mixed-citation></ref>
<ref id="c66"><mixed-citation publication-type="journal"><string-name><surname>Shin</surname>, <given-names>D.S.</given-names></string-name>, <string-name><given-names>A.</given-names> <surname>Jordan</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Basu</surname></string-name>, <string-name><given-names>R.M.</given-names> <surname>Thomas</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Bandyopadhyay</surname></string-name>, <string-name><given-names>E.F.</given-names> <surname>de Zoeten</surname></string-name>, <string-name><given-names>A.D.</given-names> <surname>Wells</surname></string-name>, and <string-name><given-names>F.</given-names> <surname>Macian</surname></string-name>. <year>2014</year>. <article-title>Regulatory T cells suppress CD4+ T cells through NFAT-dependent transcriptional mechanisms</article-title>. <source>EMBO reports</source> <volume>15</volume>:<fpage>991</fpage>–<lpage>999</lpage>.</mixed-citation></ref>
<ref id="c67"><mixed-citation publication-type="journal"><string-name><surname>Silva Morales</surname>, <given-names>M.</given-names></string-name>, and <string-name><given-names>D.</given-names> <surname>Mueller</surname></string-name>. <year>2018</year>. <article-title>Anergy into T regulatory cells: an integration of metabolic cues and epigenetic changes at the Foxp3 conserved non-coding sequence 2</article-title>. <source>F1000Research</source> <volume>7</volume>:</mixed-citation></ref>
<ref id="c68"><mixed-citation publication-type="journal"><string-name><surname>Sinclair</surname>, <given-names>L.V.</given-names></string-name>, <string-name><given-names>J.</given-names> <surname>Rolf</surname></string-name>, <string-name><given-names>E.</given-names> <surname>Emslie</surname></string-name>, <string-name><given-names>Y.B.</given-names> <surname>Shi</surname></string-name>, <string-name><given-names>P.M.</given-names> <surname>Taylor</surname></string-name>, and <string-name><given-names>D.A.</given-names> <surname>Cantrell</surname></string-name>. <year>2013</year>. <article-title>Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation</article-title>. <source>Nature immunology</source> <volume>14</volume>:<fpage>500</fpage>–<lpage>508</lpage>.</mixed-citation></ref>
<ref id="c69"><mixed-citation publication-type="journal"><string-name><surname>Singer</surname>, <given-names>M.</given-names></string-name>, <string-name><given-names>C.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Cong</surname></string-name>, <string-name><given-names>N.D.</given-names> <surname>Marjanovic</surname></string-name>, <string-name><given-names>M.S.</given-names> <surname>Kowalczyk</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Nyman</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Sakuishi</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Kurtulus</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Gennert</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Xia</surname></string-name>, <string-name><given-names>J.Y.</given-names> <surname>Kwon</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Nevin</surname></string-name>, <string-name><given-names>R.H.</given-names> <surname>Herbst</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Yanai</surname></string-name>, <string-name><given-names>O.</given-names> <surname>Rozenblatt-Rosen</surname></string-name>, <string-name><given-names>V.K.</given-names> <surname>Kuchroo</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Regev</surname></string-name>, and <string-name><given-names>A.C.</given-names> <surname>Anderson</surname></string-name>. <year>2016</year>. <article-title>A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells</article-title>. <source>Cell</source> <volume>166</volume>:<fpage>1500</fpage>–<lpage>1511</lpage>.e1509.</mixed-citation></ref>
<ref id="c70"><mixed-citation publication-type="journal"><string-name><surname>Subramanian</surname>, <given-names>A.</given-names></string-name>, <string-name><given-names>P.</given-names> <surname>Tamayo</surname></string-name>, <string-name><given-names>V.K.</given-names> <surname>Mootha</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Mukherjee</surname></string-name>, <string-name><given-names>B.L.</given-names> <surname>Ebert</surname></string-name>, <string-name><given-names>M.A.</given-names> <surname>Gillette</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Paulovich</surname></string-name>, <string-name><given-names>S.L.</given-names> <surname>Pomeroy</surname></string-name>, <string-name><given-names>T.R.</given-names> <surname>Golub</surname></string-name>, <string-name><given-names>E.S.</given-names> <surname>Lander</surname></string-name>, and <string-name><given-names>J.P.</given-names> <surname>Mesirov</surname></string-name>. <year>2005</year>. <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <volume>102</volume>:<fpage>15545</fpage>–<lpage>15550</lpage>.</mixed-citation></ref>
<ref id="c71"><mixed-citation publication-type="journal"><string-name><surname>Subramanian</surname>, <given-names>J.</given-names></string-name>, <string-name><given-names>K.</given-names> <surname>Michel</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Benoit</surname></string-name>, and <string-name><given-names>E.</given-names> <surname>Nedivi</surname></string-name>. <year>2019</year>. <article-title>CPG15/Neuritin Mimics Experience in Selecting Excitatory Synapses for Stabilization by Facilitating PSD95 Recruitment</article-title>. <source>Cell reports</source> <volume>28</volume>:<fpage>1584</fpage>–<lpage>1595</lpage>.e1585.</mixed-citation></ref>
<ref id="c72"><mixed-citation publication-type="journal"><string-name><surname>Sullivan</surname>, <given-names>M.R.</given-names></string-name>, <string-name><given-names>L.V.</given-names> <surname>Danai</surname></string-name>, <string-name><given-names>C.A.</given-names> <surname>Lewis</surname></string-name>, <string-name><given-names>S.H.</given-names> <surname>Chan</surname></string-name>, <string-name><given-names>D.Y.</given-names> <surname>Gui</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Kunchok</surname></string-name>, <string-name><given-names>E.A.</given-names> <surname>Dennstedt</surname></string-name>, <string-name><given-names>M.G.</given-names> <surname>Vander Heiden</surname></string-name>, and <string-name><given-names>A.</given-names> <surname>Muir</surname></string-name>. <year>2019</year>. <article-title>Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability</article-title>. <source>eLife</source> <volume>8</volume>:</mixed-citation></ref>
<ref id="c73"><mixed-citation publication-type="journal"><string-name><surname>Sundelacruz</surname>, <given-names>S.</given-names></string-name>, <string-name><given-names>M.</given-names> <surname>Levin</surname></string-name>, and <string-name><given-names>D.L.</given-names> <surname>Kaplan</surname></string-name>. <year>2009</year>. <article-title>Role of membrane potential in the regulation of cell proliferation and differentiation</article-title>. <source>Stem Cell Rev Rep</source> <volume>5</volume>:<fpage>231</fpage>–<lpage>246</lpage>.</mixed-citation></ref>
<ref id="c74"><mixed-citation publication-type="journal"><string-name><surname>Vahl</surname>, <given-names>J.C.</given-names></string-name>, <string-name><given-names>C.</given-names> <surname>Drees</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Heger</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Heink</surname></string-name>, <string-name><given-names>J.C.</given-names> <surname>Fischer</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Nedjic</surname></string-name>, <string-name><given-names>N.</given-names> <surname>Ohkura</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Morikawa</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Poeck</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Schallenberg</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Riess</surname></string-name>, <string-name><given-names>M.Y.</given-names> <surname>Hein</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Buch</surname></string-name>, <string-name><given-names>B.</given-names> <surname>Polic</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Schonle</surname></string-name>, <string-name><given-names>R.</given-names> <surname>Zeiser</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Schmitt-Graff</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Kretschmer</surname></string-name>, <string-name><given-names>L.</given-names> <surname>Klein</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Korn</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Sakaguchi</surname></string-name>, and <string-name><given-names>M.</given-names> <surname>Schmidt-Supprian</surname></string-name>. <year>2014</year>. <article-title>Continuous T cell receptor signals maintain a functional regulatory T cell pool</article-title>. <source>Immunity</source> <volume>41</volume>:<fpage>722</fpage>–<lpage>736</lpage>.</mixed-citation></ref>
<ref id="c75"><mixed-citation publication-type="journal"><string-name><surname>Vanasek</surname>, <given-names>T.L.</given-names></string-name>, <string-name><given-names>S.L.</given-names> <surname>Nandiwada</surname></string-name>, <string-name><given-names>M.K.</given-names> <surname>Jenkins</surname></string-name>, and <string-name><given-names>D.L.</given-names> <surname>Mueller</surname></string-name>. <year>2006</year>. <article-title>CD25+Foxp3+ regulatory T cells facilitate CD4+ T cell clonal anergy induction during the recovery from lymphopenia</article-title>. <source>Journal of immunology (Baltimore, Md. : 1950)</source> <volume>176</volume>:<fpage>5880</fpage>–<lpage>5889</lpage>.</mixed-citation></ref>
<ref id="c76"><mixed-citation publication-type="journal"><string-name><surname>Wang</surname>, <given-names>Y.</given-names></string-name>, <string-name><given-names>A.</given-names> <surname>Tao</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Vaeth</surname></string-name>, and <string-name><given-names>S.</given-names> <surname>Feske</surname></string-name>. <year>2020</year>. <article-title>Calcium regulation of T cell metabolism</article-title>. <source>Current opinion in physiology</source> <volume>17</volume>:<fpage>207</fpage>–<lpage>223</lpage>.</mixed-citation></ref>
<ref id="c77"><mixed-citation publication-type="journal"><string-name><surname>Whiteaker</surname>, <given-names>K.L.</given-names></string-name>, <string-name><given-names>S.M.</given-names> <surname>Gopalakrishnan</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Groebe</surname></string-name>, <string-name><given-names>C.C.</given-names> <surname>Shieh</surname></string-name>, <string-name><given-names>U.</given-names> <surname>Warrior</surname></string-name>, <string-name><given-names>D.J.</given-names> <surname>Burns</surname></string-name>, <string-name><given-names>M.J.</given-names> <surname>Coghlan</surname></string-name>, <string-name><given-names>V.E.</given-names> <surname>Scott</surname></string-name>, and <string-name><given-names>M.</given-names> <surname>Gopalakrishnan</surname></string-name>. <year>2001</year>. <article-title>Validation of FLIPR membrane potential dye for high throughput screening of potassium channel modulators</article-title>. <source>J Biomol Screen</source> <volume>6</volume>:<fpage>305</fpage>–<lpage>312</lpage>.</mixed-citation></ref>
<ref id="c78"><mixed-citation publication-type="journal"><string-name><surname>Workman</surname>, <given-names>C.J.</given-names></string-name>, <string-name><given-names>L.W.</given-names> <surname>Collison</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Bettini</surname></string-name>, <string-name><given-names>M.R.</given-names> <surname>Pillai</surname></string-name>, <string-name><given-names>J.E.</given-names> <surname>Rehg</surname></string-name>, and <string-name><given-names>D.A.</given-names> <surname>Vignali</surname></string-name>. <year>2011</year>. <article-title>In vivo Treg suppression assays</article-title>. <source>Methods in molecular biology (Clifton, N.J.)</source> <volume>707</volume>:<fpage>119</fpage>–<lpage>156</lpage>.</mixed-citation></ref>
<ref id="c79"><mixed-citation publication-type="journal"><string-name><surname>Yao</surname>, <given-names>J.J.</given-names></string-name>, <string-name><given-names>X.F.</given-names> <surname>Gao</surname></string-name>, <string-name><given-names>C.W.</given-names> <surname>Chow</surname></string-name>, <string-name><given-names>X.Q.</given-names> <surname>Zhan</surname></string-name>, <string-name><given-names>C.L.</given-names> <surname>Hu</surname></string-name>, and <string-name><given-names>Y.A.</given-names> <surname>Mei</surname></string-name>. <year>2012</year>. <article-title>Neuritin activates insulin receptor pathway to up-regulate Kv4.2-mediated transient outward K+ current in rat cerebellar granule neurons</article-title>. <source>The Journal of biological chemistry</source> <volume>287</volume>:<fpage>41534</fpage>–<lpage>41545</lpage>.</mixed-citation></ref>
<ref id="c80"><mixed-citation publication-type="journal"><string-name><surname>Yu</surname>, <given-names>W.</given-names></string-name>, <string-name><given-names>Z.</given-names> <surname>Wang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Yu</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Zhao</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Xie</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>Z.</given-names> <surname>Chi</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Chen</surname></string-name>, <string-name><given-names>T.</given-names> <surname>Xu</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Jiang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Guo</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Li</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Fang</surname></string-name>, <string-name><given-names>D.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Guo</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Yang</surname></string-name>, <string-name><given-names>X.</given-names> <surname>Zhang</surname></string-name>, <string-name><given-names>Y.</given-names> <surname>Wu</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Yang</surname></string-name>, and <string-name><given-names>D.</given-names> <surname>Wang</surname></string-name>. <year>2022</year>. <article-title>Kir2.1-mediated membrane potential promotes nutrient acquisition and inflammation through regulation of nutrient transporters</article-title>. <source>Nature communications</source> <volume>13</volume>:<fpage>3544</fpage>.</mixed-citation></ref>
<ref id="c81"><mixed-citation publication-type="journal"><string-name><surname>Zha</surname>, <given-names>Y.</given-names></string-name>, <string-name><given-names>R.</given-names> <surname>Marks</surname></string-name>, <string-name><given-names>A.W.</given-names> <surname>Ho</surname></string-name>, <string-name><given-names>A.C.</given-names> <surname>Peterson</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Janardhan</surname></string-name>, <string-name><given-names>I.</given-names> <surname>Brown</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Praveen</surname></string-name>, <string-name><given-names>S.</given-names> <surname>Stang</surname></string-name>, <string-name><given-names>J.C.</given-names> <surname>Stone</surname></string-name>, and <string-name><given-names>T.F.</given-names> <surname>Gajewski</surname></string-name>. <year>2006</year>. <article-title>T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha</article-title>. <source>Nature immunology</source> <volume>7</volume>:<fpage>1166</fpage>–<lpage>1173</lpage>.</mixed-citation></ref>
<ref id="c82"><mixed-citation publication-type="journal"><string-name><surname>Zheng</surname>, <given-names>Y.</given-names></string-name>, <string-name><given-names>G.M.</given-names> <surname>Delgoffe</surname></string-name>, <string-name><given-names>C.F.</given-names> <surname>Meyer</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Chan</surname></string-name>, and <string-name><given-names>J.D.</given-names> <surname>Powell</surname></string-name>. <year>2009</year>. <article-title>Anergic T cells are metabolically anergic</article-title>. <source>Journal of immunology (Baltimore, Md. : 1950)</source> <volume>183</volume>:<fpage>6095</fpage>–<lpage>6101</lpage>.</mixed-citation></ref>
<ref id="c83"><mixed-citation publication-type="journal"><string-name><surname>Zheng</surname>, <given-names>Y.</given-names></string-name>, <string-name><given-names>S.</given-names> <surname>Josefowicz</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Chaudhry</surname></string-name>, <string-name><given-names>X.P.</given-names> <surname>Peng</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Forbush</surname></string-name>, and <string-name><given-names>A.Y.</given-names> <surname>Rudensky</surname></string-name>. <year>2010</year>. <article-title>Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate</article-title>. <source>Nature</source> <volume>463</volume>:<fpage>808</fpage>–<lpage>812</lpage>.</mixed-citation></ref>
<ref id="c84"><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname>, <given-names>S.</given-names></string-name>, and <string-name><given-names>J.</given-names> <surname>Zhou</surname></string-name>. <year>2014</year>. <article-title>Neuritin, a neurotrophic factor in nervous system physiology</article-title>. <source>Current medicinal chemistry</source> <volume>21</volume>:<fpage>1212</fpage>–<lpage>1219</lpage>.</mixed-citation></ref>
<ref id="c85"><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname>, <given-names>Y.</given-names></string-name>, <string-name><given-names>C.O.</given-names> <surname>Wong</surname></string-name>, <string-name><given-names>K.J.</given-names> <surname>Cho</surname></string-name>, <string-name><given-names>D.</given-names> <surname>van der Hoeven</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Liang</surname></string-name>, <string-name><given-names>D.P.</given-names> <surname>Thakur</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Luo</surname></string-name>, <string-name><given-names>M.</given-names> <surname>Babic</surname></string-name>, <string-name><given-names>K.E.</given-names> <surname>Zinsmaier</surname></string-name>, <string-name><given-names>M.X.</given-names> <surname>Zhu</surname></string-name>, <string-name><given-names>H.</given-names> <surname>Hu</surname></string-name>, <string-name><given-names>K.</given-names> <surname>Venkatachalam</surname></string-name>, and <string-name><given-names>J.F.</given-names> <surname>Hancock</surname></string-name>. <year>2015</year>. <article-title>SIGNAL TRANSDUCTION. Membrane potential modulates plasma membrane phospholipid dynamics and K-Ras signaling</article-title>. <source>Science (New York, N.Y.)</source> <volume>349</volume>:<fpage>873</fpage>–<lpage>876</lpage>.</mixed-citation></ref>
<ref id="c86"><mixed-citation publication-type="journal"><string-name><surname>Zito</surname>, <given-names>A.</given-names></string-name>, <string-name><given-names>D.</given-names> <surname>Cartelli</surname></string-name>, <string-name><given-names>G.</given-names> <surname>Cappelletti</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Cariboni</surname></string-name>, <string-name><given-names>W.</given-names> <surname>Andrews</surname></string-name>, <string-name><given-names>J.</given-names> <surname>Parnavelas</surname></string-name>, <string-name><given-names>A.</given-names> <surname>Poletti</surname></string-name>, and <string-name><given-names>M.</given-names> <surname>Galbiati</surname></string-name>. <year>2014</year>. <article-title>Neuritin 1 promotes neuronal migration</article-title>. <source>Brain Structure and Function</source> <volume>219</volume>:<fpage>105</fpage>–<lpage>118</lpage>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.96812.1.sa2</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Sakaguchi</surname>
<given-names>Shimon</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Osaka University</institution>
</institution-wrap>
<city>Osaka</city>
<country>Japan</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Solid</kwd>
</kwd-group>
</front-stub>
<body>
<p>The neurotrophic factor Neuritin can moderate T-cell tolerance and immunity through both regulatory T (Treg) and effector T cells, promoting Treg cell expansion and suppression while dampening effector T cells to mediate the inflammatory response. Neuritin expression influences the membrane potential, ion channels, and nutrient transporter expression patterns of CD4+ T cells, contributing to differential metabolic states in Treg and effector T cells. These findings are <bold>solid</bold> and <bold>important</bold> for understanding immune regulation involving Treg cells and effector T cells.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.96812.1.sa1</article-id>
<title-group>
<article-title>Reviewer #1 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>The manuscript by Yu et al seeks to investigate the role of neuritin (Nrn1), identified as a marker of anergic cells, in the biology of regulatory (Tregs) and conventional (Tconv) T cells. Although the role of Nrn1 expressed by Tregs has already been explored (Gonzalez-Figueroa 2021 cited in the manuscript), this manuscript shows original new data suggesting that this molecule would be important in promoting Treg function and inhibiting Tconv effector function by acting at the level of membrane potential and molecule transport across the plasma membrane. However, it is disappointing that reading this manuscript leaves an impression of incomplete work done too quickly. Multiple models have been used, but none has been studied thoroughly enough to provide really conclusive and unambiguous data. For example, 5 different models were used to study T cells in vivo. It would have been preferable to use fewer, but to go further in the study of mechanisms. In the absence of a more in-depth study, the conclusions drawn by the authors are often open to question. Major points concern the fact that there are enough biological replicates for most experiments, some critical controls and data are lacking, and the authors have used iTregs rather than nTregs for many experiments (see below). This is unfortunate because the role of neuritin in T cell biology studied here is new and interesting.</p>
<p>Major points (in the order in which they appear in the text):</p>
<p>(1) A real weakness of this work is the fact that in most of the results shown, there are few biological replicates with differences that are often small between Ctrl and Nrn1 -/-. The systematic use of student's t-test may lead to thinking that the differences are significant, which is often misleading given the small number of samples, which makes it impossible to know whether the distributions are Gaussian and whether a parametric test can be used. RNAseq bulk data are based on biological duplicates, which is open to criticism.</p>
<p>(2) The authors use Nrn1+/+ and Nrn1+/- cells indiscriminately as control cells on the basis of similar biology between Nrn1+/+ and Nrn1+/- cells at homeostasis. However, it is quite possible that the Nrn1+/- cells have a phenotype in situations of in vitro activation or in vivo inflammation (cancer, EAE). It would be important to discriminate Nrn1+/- and Nrn1+/+ cells in the data or to show that both cell types have the same phenotype in these conditions too.</p>
<p>(3) Figure 1A-D. Since the authors are using the Nrp1 KO mice, it would be important to confirm the specificity of the anti-Nrn1 mAb by FACS. Once verified, it would be important to add FACS results with this mAb in Figures 1A-C to have single-cell and quantitative data as well.</p>
<p>(4) Figure 1E-H. The authors assume that this immunization protocol induces anergic cells, but they provide no experimental evidence for this. It would be useful to show that T cells are indeed anergic in this model, especially those that are OVA-specific. The lack of IL-2 production by Cltr cells could be explained by the presence of fewer OVA-specific cells, rather than by an anergic status.</p>
<p>(5) Figure 2A-C and Figure 3. The use of iTregs to try to understand what is happening in vivo is problematic. iTregs are cells that have probably no equivalent in vivo, and so may have no physiological relevance. In any case, they are different from pTreg cells generated in vivo. Working with pTreg may be challenging, that is why I would suggest generating data with purified nTreg. Moreover, it was shown in the article of Gonzalez-Figueroa 2021 that Nrn1-/- nTreg retained a normal suppressive function, which would not be what is concluded by the authors of this manuscript. Moreover, we do not even know what the % of Foxp3 cells is in the iTreg used (after differentiation and 20h of re-stimulation) and whether this % is the same between Ctlr and Nrn1 KO cells.</p>
<p>(6) Figure 2D-L. The model is designed to study the role of Nrn1 in nTreg. However, the % of Foxp3+ among CD45.2 nTreg cells fell to 5-15% of CD4+ cells (Figure 2F). Since we do not know what is the % of Foxp3 among the injected cells, we do not know whether this very low % is due to very high Treg instability or to preferential expansion of contaminating Tconvs. It is possible that the % of Tconv contaminant is high since Treg was sorted using beads and not FACS in some experiments. As it is very likely that there are Tconv contaminants that would be Nrn1-/- in the group transferred with Nrn1-/- &quot;nTreg&quot;, the higher tumor rejection could be due to an overactivation of Nrn1-/- Tconvs (rather than a defect in Nrn1-/- Treg function).</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.96812.1.sa0</article-id>
<title-group>
<article-title>Reviewer #2 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>This manuscript explores the role of Nrn1 in T cell tolerance. A previous study has demonstrated that Nrn1 is up-regulated in the Tfr fraction of Foxp3+ T regulatory cells. These authors now confirm the expression of Nrn1 in Tregs as well as report here that Nrn1 is also greatly over-expressed in anergic CD4 T cells, and this is the stepping-off point for this investigation.</p>
<p>Most remarkably, experiments show that anergy induction is defective when T cells cannot express Nrn1. Furthermore, differentiation to a Foxp3+ Treg phenotype is inhibited in the absence of Nrn1, and the Tregs that do develop appear functionally defective. With such defects in the anergy induction and Treg differentiation and function, auto-reactive effector T cell activation is unrestrained, and Nrn1-/- mice are more susceptible to severe EAE development.</p>
<p>Strengths:</p>
<p>The characterizations of T cell Nrn1 expression both in vitro and in vivo are comprehensive and convincing. The in vivo functional studies of anergy development, Treg suppression, and EAE development are also well done to strengthen the notion that Nrn1 is an important regulator of CD4 responsiveness.</p>
<p>Weaknesses:</p>
<p>The major weakness of this study stems from a lack of a clear molecular mechanism involving Nrn1. Previous studies of Nrn1 have suggested its role as a soluble molecule involved in intracellular communication, perhaps influencing cellular ion channel function and/or triggering downstream NFAT and mTOR activation. However, a unique receptor for Nrn1 has not been discovered and it remains unclear whether it acts in a cell-intrinsic or cell-extrinsic fashion for any particular cell type.</p>
<p>Data shown here provide evidence of alterations in the electrical and metabolic state of T cells when the Nrn1 gene is deleted. Nrn1-/- Tregs and Teffector cells each express a unique pattern of genes associated with Neurotransmitter receptor, Metal ion transmembrane transport, Amino acid transport, and mTORC1 signaling activities, different than that seen in wild-type mice. Although the biochemical and informatics studies are well-performed, it is my opinion that these results are inconclusive in part due to the absence of key &quot;naive&quot; control groups. This limits my ability to understand the significance of these data.</p>
<p>Specifically, studies of the electrical and metabolic state of Nrn1-/- inducible Treg cells (iTregs) would benefit from similar data collected from wild-type and Nrn1-/- naive CD4 T cells. Even though naive T cells don't express Nrn1, they may be positively influenced by soluble Nrn1. Does deletion of Nrn1 lead to changes in metabolic and electrical state in naive T cells? Is that why Nrn1 deletion in mice blocks naive T cell activation?</p>
<p>Since the loss of Nrn1 inhibits the activation of T cells, are Nrn1-/- iTregs transcriptionally, electrically, and metabolically similar to naive T cells due to their suboptimal activation? Does this account for their persistent functional defects? Or is up-regulation of Nrn1 (and cell-intrinsic Nrn1 signaling) necessary to complete Treg differentiation and to promote T regulatory function (similar to how cell-intrinsic Nrn1 facilitates anergy induction)? The study of naive cells in parallel with iTregs would address these possibilities.</p>
<p>A comparison of Nrn1-/- naive cells to Teffector cells should also be undertaken to reveal how it is that Nrn1-/- Teffector cells regain the capacity to respond effectively to stimulation (e.g. increased mTOR activation) despite their early activation defects.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.96812.1.sa3</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Hong</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nishio</surname>
<given-names>Hiroshi</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Barbi</surname>
<given-names>Joseph</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mitchell-Flack</surname>
<given-names>Marisa</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vignali</surname>
<given-names>Paolo D. A.</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zheng</surname>
<given-names>Ying</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lebid</surname>
<given-names>Andriana</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chang</surname>
<given-names>Kwang-Yu</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fu</surname>
<given-names>Juan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Higgins</surname>
<given-names>Makenzie</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Ching-Tai</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Xuehong</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Zhiguang</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Blosser</surname>
<given-names>Lee</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tam</surname>
<given-names>Ada</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Drake</surname>
<given-names>Charles G.</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9610-3677</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Pardoll</surname>
<given-names>Drew M.</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p><bold>To Reviewer #1:</bold></p>
<p>Thank you for your thorough review and comments on our work, which you described as “the role of neuritin in T cell biology studied here is new and interesting.”.  We have summarized your comments into two categories: biology and investigation approach, experimental rigor, and data presentation.</p>
<p>Biology and Investigation approach comments:</p>
<p>(1) Questions regarding the T cell anergy model:</p>
<disp-quote content-type="editor-comment">
<p>Major point “(4) Figure 1E-H. The authors assume that this immunization protocol induces anergic cells, but they provide no experimental evidence for this. It would be useful to show that T cells are indeed anergic in this model, especially those that are OVA-specific. The lack of IL-2 production by Cltr cells could be explained by the presence of fewer OVA-specific cells, rather than by an anergic status.”</p>
</disp-quote>
<p>T cell anergy is a well-established concept first described by Schwartz’s group. It refers to the hyporesponsive T cell functional state in antigen-experienced CD4 T cells (Chappert and Schwartz, 2010; Fathman and Lineberry, 2007; Jenkins and Schwartz, 1987; Quill and Schwartz, 1987).  Anergic T cells are characterized by their inability to expand and to produce IL2 upon subsequent antigen re-challenge. In this paper, we have borrowed the existing <italic>in vivo</italic> T cell anergy induction model used by Mueller’s group for T cell anergy induction (Vanasek et al., 2006).  Specifically, Thy1.1+ Ctrl or Nrn1-/- TCR transgenic OTII cells were co-transferred with the congenically marked Thy1.2+ WT polyclonal Treg cells into TCR-/- mice.  After anergy induction, the congenically marked TCR transgenic T cells were recovered by sorting based on Thy1.1+ congenic marker, and subsequently re-stimulation <italic>ex vivo</italic> with OVA323-339 peptide. We evaluated the T cell anergic state based on OTII cell expansion <italic>in vivo</italic> and IL2 production upon OVA323-339 restimulation <italic>ex vivo</italic>.</p>
<disp-quote content-type="editor-comment">
<p>“The authors assume that this immunization protocol induces anergic cells, but they provide no experimental evidence for this.”</p>
</disp-quote>
<p>Because the anergy model by Mueller's group is well established (Vanasek et al., 2006), we did not feel that additional effort was required to validate this model as the reviewer suggested. Moreover, the limited IL2 production among the control cells upon restimulation confirms the validity of this model.</p>
<disp-quote content-type="editor-comment">
<p>“The lack of IL-2 production by Cltr cells could be explained by the presence of fewer OVAspecific cells, rather than by an anergic status”.</p>
</disp-quote>
<p>Cells from Ctrl and Nrn1-/- mice on a homogeneous TCR transgenic (OTII) background were used in these experiments. The possibility that substantial variability of TCR expression or different expression levels of the transgenic TCR could have impacted IL2 production rather than anergy induction is unlikely.</p>
<p>Overall, we used this <italic>in vivo</italic> anergy model to evaluate the Nrn1-/- T cell functional state in comparison to Ctrl cells under the anergy induction condition following the evaluation of Nrn1 expression, particularly in anergic T cells.  Through studies using this anergy model, we observed a significant change in Treg induction among OTII cells. We decided to pursue the role of Nrn1 in Treg cell development and function rather than the biology of T cell anergy as evidenced by subsequent experiments.</p>
<disp-quote content-type="editor-comment">
<p>Minor points “(6) On which markers are anergic cells sorted for RNAseq analysis?”</p>
</disp-quote>
<p>Cells were sorted out based on their congenic marker marking Ctrl or Nrn1-/- OTII cells transferred into the host mice.  We did not specifically isolate anergic cells for sequencing.</p>
<p>(2) Question regarding the validity of iTreg differentiation model.</p>
<disp-quote content-type="editor-comment">
<p>Major point: “(5) Figure 2A-C and Figure 3. The use of iTregs to try to understand what is happening in vivo is problematic. iTregs are cells that have probably no equivalent in vivo, and so may have no physiological relevance. In any case, they are different from pTreg cells generated in vivo. Working with pTreg may be challenging, that is why I would suggest generating data with purified nTreg. Moreover, it was shown in the article of Gonzalez-Figueroa 2021 that Nrn1-/- nTreg retained a normal suppressive function, which would not be what is concluded by the authors of this manuscript. Moreover, we do not even know what the % of Foxp3 cells is in the iTreg used (after differentiation and 20h of re-stimulation) and whether this % is the same between Ctlr and Nrn1 KO cells.”.</p>
</disp-quote>
<p>We thank Reviewer #1 for their feedback. While it is true that iTregs made <italic>in vitro</italic> and <italic>in vivo</italic> generated pTregs display several distinctions (<italic>e. g.,</italic> differences in Foxp3 expression stability, for example), we strongly disagree with this statement by Revieweer#1 “The use of iTregs to try to understand what is happening in vivo is problematic. iTregs are cells that have probably no equivalent in vivo, and so may have no physiological relevance.” The induced Treg cell (iTreg) model was established over 20 years ago (Chen et al., 2003; Zheng et al., 2002), and the model is widely adopted with over 2000 citations. Further, it has been instrumental in understanding different aspects of regulatory T cell biology (Hurrell et al., 2022; John et al., 2022; Schmitt and Williams, 2013; Sugiura et al., 2022).</p>
<p>Because we have observed reduced pTreg generation <italic>in vivo</italic>, we choose to use the <italic>in vitro</italic> iTreg model system to understand the mechanistic changes involved in Treg cell differentiation and function, specifically, neuritin’s role in this process. We have made no claim that iTreg cell biology is identical to pTreg generated <italic>in vivo</italic> or nTreg cells. However, the iTreg culture system has proved to be a good <italic>in vitro</italic> system for deciphering molecular events involved in complex processes. As such, it remains a commonly used approach by many research groups in the Treg cell field (Hurrell et al., 2022; John et al., 2022; Sugiura et al., 2022). Moreover, applying the iTreg <italic>in vitro</italic> culture system has been instrumental in helping us identify the cell electrical state change in Nrn1-/- CD4 cells and revealed the biological link between Nrn1 and the ionotropic AMPA receptor (AMPAR), which we will discuss in the subsequent discussion. It is technically challenging to use nTreg cells for T cell electrical state studies due to their heterogeneous nature from development in an <italic>in vivo</italic> environment and the effect of manipulation during the nTreg cell isolation process, which can both affect the T cell electrical state.</p>
<disp-quote content-type="editor-comment">
<p>“Moreover, it was shown in the article of Gonzalez-Figueroa 2021 that Nrn1-/- nTreg retained a normal suppressive function, which would not be what is concluded by the authors of this manuscript.”</p>
</disp-quote>
<p>We have also carried out nTreg studies <italic>in vitro</italic> in addition to iTreg cells. Similar to Gonzalez-Figueroa et al.'s findings, we did not observe differences in suppression function between Nrn1-/- and WT nTreg using the <italic>in vitro</italic> suppression assay. However, Nrn1-/- nTreg cells revealed reduced suppression function <italic>in vivo</italic> (Fig. 2D-L). In fact, Gonzalez-Figueroa <italic>et al</italic>. observed reduced plasma cell formation after OVA immunization in Treg-specific Nrn1-/- mice, implicating reduced suppression from Nrn1-/- follicular regulatory T (Tfr) cells. Thus, our observation of the reduced suppression function of Nrn1-/- nTreg toward effector T cell expansion, as presented in Fig. 2D-L, does not contradict the results from Gonzalez-Figueroa <italic>et al</italic>. Rather, the conclusions of these two studies agree that Nrn1 can play important roles in immune suppression observable <italic>in vivo</italic> that are not captured readily by the <italic>in vitro</italic> suppression assay.</p>
<disp-quote content-type="editor-comment">
<p>“Moreover, we do not even know what the % of Foxp3 cells is in the iTreg used (after differentiation and 20h of re-stimulation) and whether this % is the same between Ctlr and Nrn1 KO cells.”</p>
</disp-quote>
<p>We have stated in the manuscript on page 7 line 208 that “Similar proportions of Foxp3+ cells were observed in Nrn1-/- and Ctrl cells under the iTreg culture condition, suggesting that Nrn1 deficiency does not significantly impact Foxp3+ cell differentiation”. In the revised manuscript, we will include the data on the proportion of Foxp3+ cells before iTreg restimulation.</p>
<p>(3) Confirmation of transcriptomic data regarding amino acids or electrolytes transport change</p>
<disp-quote content-type="editor-comment">
<p>Minor point“(3) Would not it be possible to perform experiments showing the ability of cells to transport amino acids or electrolytes across the plasma membrane? This would be a more interesting demonstration than transcriptomic data.”</p>
</disp-quote>
<p>We appreciate Review# 1’s suggestion regarding “perform experiments showing the ability of cells to transport amino acids or electrolytes across the plasma membrane”.  We have indeed already performed such experiments corroborating the transcriptomics data on differential amino acid and nutrient transporter expression. Specifically, we loaded either iTreg or Th0 cells with membrane potential (MP) dye and measured MP level change after adding the complete set of amino acids (complete AA).  Upon entry, the charge carried by AAs may transiently affect cell membrane potential. Different AA transporter expression patterns may show different MP change patterns upon AA entry, as we showed in Author response image 1. We observed reduced MP change in Nrn1-/- iTreg compared to the Ctrl, whereas in the context of Th0 cells, Nrn1-/- showed enhanced MP change than the Ctrl. We can certainly include these data in the revised manuscript.</p>
<fig id="sa3fig1">
<label>Author response image 1.</label>
<caption>
<title>Membrane potential change induced by amino acids entry.</title>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-96812-sa3-fig1.jpg" mimetype="image"/>
</fig>
<p>(4) EAE experiment data assessment</p>
<disp-quote content-type="editor-comment">
<p>Minor point ”(5) Figure 5F. How are cells re-stimulated? If polyclonal stimulation is used, the experiment is not interesting because the analysis is done with lymph node cells. This analysis should either be performed with cells from the CNS or with MOG restimulation with lymph node cells.”</p>
</disp-quote>
<p>In the EAE study, the Nrn1-/- mice exhibit similar disease onset but a protracted non-resolving disease phenotype compared to the WT control mice.  Several reasons may contribute to this phenotype: 1. Enhanced T effector cell infiltration/persistence in the central nervous system (CNS); 2. Reduced Treg cell-mediated suppression to the T effector cells in the CNS; 3. Protracted non-resolving inflammation at the immunization site has the potential to continue sending T effector cells into CNS, contributing to persistent inflammation. Based on this reasoning, we examined the infiltrating T effector cell number and Treg cell proportion in the CNS.  We also restimulated cells from draining lymph nodes close to the inflammation site, looking for evidence of persistent inflammation.  When mice were harvested around day 16 after immunization, the inflammation at the local draining lymph node should be at the contraction stage.  We stimulated cells with PMA and ionomycin intended to observe all potential T effector cells involved in the draining lymph node rather than only MOG antigen-specific cells.  We disagree with Reviewer #1’s assumption that “This analysis should either be performed with cells from the CNS or with MOG restimulation with lymph node cells.”. We think the experimental approach we have taken has been appropriately tailored to the biological questions we intended to answer.</p>
<p>Experimental rigor and data presentation.</p>
<p>(1) Data labeling and additional supporting data</p>
<disp-quote content-type="editor-comment">
<p>Major points (2) The authors use Nrn1+/+ and Nrn1+/- cells indiscriminately as control cells on the basis of similar biology between Nrn1+/+ and Nrn1+/- cells at homeostasis. However, it is quite possible that the Nrn1+/- cells have a phenotype in situations of in vitro activation or in vivo inflammation (cancer, EAE). It would be important to discriminate Nrn1+/- and Nrn1+/+ cells in the data or to show that both cell types have the same phenotype in these conditions too.</p>
<p>(3) Figure 1A-D. Since the authors are using the Nrp1 KO mice, it would be important to confirm the specificity of the anti-Nrn1 mAb by FACS. Once verified, it would be important to add FACS results with this mAb in Figures 1A-C to have single-cell and quantitative data as well.</p>
<p>Minor points</p>
<p>(1) Line 119, 120 of the text. It is said that one of the most up-regulated genes in anergic cells is Nrn1 but the data is not shown.</p>
<p>(2) For all figures showing %, the titles of the Y axes are written in an odd way. For example, it is written &quot;Foxp3% CD4&quot;. It would be more conventional and clearer to write &quot;% Foxp3+ / CD4+&quot; or &quot;% Foxp3+ among CD4+&quot;.</p>
<p>(4) For certain staining (Figure 3E, H) it would be important to show the raw data, in addition to MFI or % values.</p>
</disp-quote>
<p>We can adapt the labeling and provide additional data, including Nrn1 staining on Treg cells and flow graphs for pmTOR and pS6 staining (Fig. 3H), as requested by Reviewer #1.</p>
<p>(2) Experimental rigor:</p>
<p>General comments:</p>
<disp-quote content-type="editor-comment">
<p>“However, it is disappointing that reading this manuscript leaves an impression of incomplete work done too quickly.”</p>
</disp-quote>
<p>We were discouraged to receive the comment, “this manuscript leaves an impression of incomplete work done too quickly.” Our study of this novel molecule began without any existing biological tools such as antibodies, knockout mice, <italic>etc</italic>.  Over the past several years, we have established our own antibodies for Nrn1 detection, obtained and characterized Nrn1 knockout mice, and utilized multiple approaches to identify the molecular mechanism of Nrn1 function. Through the use of the <italic>in vitro</italic> iTreg system described in this manuscript, we identified the association of Nrn1 deficiency with cell electrical state change, potentially connected to AMPAR function. We have further corroborated our findings by generating Nrn1 and AMPAR T cell specific double knockout mice and confirmed that T cell specific AMPAR deletion could abrogate the phenotype caused by the Nrn1 deficiency (see Author response image 2).  We did not include the double knockout data in the current manuscript because AMPAR function has not yet been studied thoroughly in T cell biology, and we feel this topic warrants examination in its own right.  However, the unpublished data support the finding that Nrn1 modulates the T cell electrical state and, consequently, metabolism, ultimately influencing tolerance and immunity.  In its current form, the manuscript represents the first characterization of the novel molecule Nrn1 in anergic cells, Tregs, and effector T cells. While this work has led to several exciting additional questions, we disagree that the novel characterization we have presented Is incomplete. We feel that our present data set, which squarely highlights Nrn1’s role as an important immune regulator while shedding unprecedented light on the molecular events involved, will be of considerable interest to a broad field of researchers.</p>
<disp-quote content-type="editor-comment">
<p>“Multiple models have been used, but none has been studied thoroughly enough to provide really conclusive and unambiguous data. For example, 5 different models were used to study T cells in vivo. It would have been preferable to use fewer, but to go further in the study of mechanisms.”</p>
</disp-quote>
<p>We have indeed used multiple <italic>in vivo</italic> models to reveal Nrn1's function in Treg differentiation, Treg suppression function, T effector cell differentiation and function, and the overall impact on autoimmune disease. Because the impact of ion channel function is often context-dependent, we examined the biological outcome of Nrn1 deficiency in several <italic>in vivo</italic> contexts.  We would appreciate it if Reviewer#1 would provide a specific example, given the Nrn1 phenotype, of how to proceed deeper to investigate the electrical change in the <italic>in vivo</italic> models.</p>
<disp-quote content-type="editor-comment">
<p>“Major points (1) A real weakness of this work is the fact that in most of the results shown, there are few biological replicates with differences that are often small between Ctrl and Nrn1 -/-. The systematic use of student's t-test may lead to thinking that the differences are significant, which is often misleading given the small number of samples, which makes it impossible to know whether the distributions are Gaussian and whether a parametric test can be used. RNAseq bulk data are based on biological duplicates, which is open to criticism.”</p>
</disp-quote>
<p>We respectfully disagree with Reviewer #1 on the question of statistical power and significance to our work. We have used 5-8 mice/group for each <italic>in vivo</italic> model and 3-4 technical replicates for the <italic>in vitro</italic> studies, with a minimum of 2-3 replicate experiments. These group sizes and replication numbers are in line with those seen in high-impact publications. While some differences between Ctrl and Nrn1-/- appear small, they have significant biological consequences, as evidenced by the various Nrn1-/- <italic>in vivo</italic> phenotypes. Furthermore, we believe we have subjected our data to the appropriate statistical tests to ensure rigorous analysis and representation of our findings.</p>
<p><bold>To Reviewer #2.</bold></p>
<p>We thank Reviewer #2 for the careful review of the manuscript. We especially appreciate the comments that “The characterizations of T cell Nrn1 expression both in vitro and in vivo are comprehensive and convincing. The in vivo functional studies of anergy development, Treg suppression, and EAE development are also well done to strengthen the notion that Nrn1 is an important regulator of CD4 responsiveness.”</p>
<disp-quote content-type="editor-comment">
<p>“The major weakness of this study stems from a lack of a clear molecular mechanism involving Nrn1. “</p>
</disp-quote>
<p>We fully understand this comment from Reviewer #2. The main mechanism we identified contributing to the functional defect of Nrn1-/- T cells involves novel effects on the electric and metabolic state of the cells. Although we referenced neuronal studies that indicate Nrn1 is the auxiliary protein for the ionotropic AMPA-type glutamate receptor (AMPAR) and may affect AMPAR function, we did not provide any evidence in this manuscript as the topic requires further in-depth study.</p>
<p>For the benefit of this discussion, we include our preliminary Nrn1 and AMPAR double knockout data (Author response image 2), which indicates that abrogating AMPAR expression can compensate for the defect caused by Nrn1 deficiency <italic>in vitro</italic> and <italic>in vivo</italic>. This preliminary data supports the notion that Nrn1 modulates AMPAR function, which causes changes in T cell electric and metabolic state, influencing T cell differentiation and function.</p>
<fig id="sa3fig2">
<label>Author response image 2.</label>
<caption>
<title>Deletion of AMPAR expression in T cells compensates for the defect caused by Nrn1 deficiency.</title>
<p>Nrn1-/- mice were crossed with T cell-specific AMPAR knockout mice (AMPARfl/flCD4Cre+) mice. The following mice were generated and used in the experiment: T cell specific AMPAR-knockout and Nrn1 knockout mice (AKONKO), Nrn1 knockout mice (AWTNKO), Ctrl mice (AWTNWT). <bold>a.</bold> Deletion of AMPAR compensates for the iTreg cell defect observed in Nrn1-/- CD4 cells. iTreg live cell proportion, cell number, and Ki67 expression among Foxp3+ cells 3 days after aCD3 restimulation. <bold>b.</bold> Deletion of AMPAR in T cells abrogates the enhanced autoimmune response in Nrn1-/- Mouse in the EAE disease model. Mouse relative weight change and disease score progression after EAE disease induction.</p>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-96812-sa3-fig2.jpg" mimetype="image"/>
</fig>
<p>Ion channels can influence cell metabolism through multiple means (Vaeth and Feske, 2018; Wang et al., 2020). First, ion channels are involved in maintaining cell resting membrane potential. This electrical potential difference across the cell membrane is essential for various cellular processes, including metabolism (Abdul Kadir et al., 2018; Blackiston et al., 2009; Nagy et al., 2018; Yu et al., 2022). Second, ion channels facilitate the movement of ions across cell membranes. These ions are essential for various metabolic processes. For example, ions like calcium (Ca2+), potassium (K+), and sodium (Na+) play crucial roles in signaling pathways that regulate metabolism (Kahlfuss et al., 2020). Third, ion channel activity can influence cellular energy balance due to ATP consumption associated with ion transport to maintain ion balances (Erecińska and Dagani, 1990; Gerkau et al., 2019). This, in turn, can impact processes like ATP production, which is central to cellular metabolism. Thus, ion channel expression and function determine the cell’s bioelectric state and contribute to cell metabolism (Levin, 2021).</p>
<p>Because the AMPAR function has not been thoroughly studied using a genetic approach in T cells, we do not intend to include the double knockout data in this manuscript before fully characterizing the T cell-specific AMPAR knockout mice.</p>
<disp-quote content-type="editor-comment">
<p>“Although the biochemical and informatics studies are well-performed, it is my opinion that these results are inconclusive in part due to the absence of key &quot;naive&quot; control groups. This limits my ability to understand the significance of these data.</p>
<p>Specifically, studies of the electrical and metabolic state of Nrn1-/- inducible Treg cells (iTregs) would benefit from similar data collected from wild-type and Nrn1-/- naive CD4 T cells.”</p>
</disp-quote>
<p>We appreciate the reviewer’s comments. This comment reflects two concerns in data interpretation:</p>
<p>(1) Are Nrn1-/- naïve T cells fundamentally different from WT cells? Does this fundamental difference contribute to the observed electrical and metabolic phenotype in iTreg or Th0 cells? This is a very good question we will perform the experiments as the reviewer suggested. While Nrn1 is expressed at a basal (low) level in naïve T cells, deletion of Nrn1 may cause changes in naïve T cell phenotype.</p>
<p>(2) Is the Nrn1-/- phenotype caused by Nrn1 functional deficiency or due to the secondary effect of Nrn1 deletion, such as non-physiological cell membrane structure changes?</p>
<p>We have done the following experiment to address this concern.  We have cultured WT T cells in the presence of Nrn1 antibody and compared the outcome with Nrn1-/- iTreg cells (Author response image 3). WT iTreg cells under antibody blockade exhibited similar changes as Nrn1-/- iTreg cells, confirming the physiological relevance of the Nrn1-/- phenotype.</p>
<fig id="sa3fig3">
<label>Author response image 3.</label>
<caption>
<title>Nrn1 antibody blockade in WT iTreg cell culture caused similar phenotypic change as in Nrn1-/- iTreg cells.</title>
<p>Nrn1-/- and WT CD4 cells were differentiated under iTreg condition in the presence of anti-Nrn1 (aNrn1) antibody or isotype control for 3 days. Cells were restimulated with anti-CD3 and in the presence of aNrn1 or isotype. a. MP measured 18hr after anti-CD3 restimulation. b. live CD4 cell number and proportion of Ki67 expression among live cells three days after restimulation. c. The proportion of Foxp3+ cells among live cells three days after restimulation.</p>
</caption>
<graphic mime-subtype="jpg" xlink:href="elife-96812-sa3-fig3.jpg" mimetype="image"/>
</fig>
<p>Reference:</p>
<p>Abdul Kadir, L., M. Stacey, and R. Barrett-Jolley. 2018. Emerging Roles of the Membrane Potential: Action Beyond the Action Potential. <italic>Front Physiol</italic> 9:1661.</p>
<p>Blackiston, D.J., K.A. McLaughlin, and M. Levin. 2009. Bioelectric controls of cell proliferation: ion channels, membrane voltage and the cell cycle. <italic>Cell Cycle</italic> 8:3527-3536.</p>
<p>Chappert, P., and R.H. Schwartz. 2010. Induction of T cell anergy: integration of environmental cues and infectious tolerance. <italic>Current opinion in immunology</italic> 22:552-559.</p>
<p>Chen, W., W. Jin, N. Hardegen, K.J. Lei, L. Li, N. Marinos, G. McGrady, and S.M. Wahl. 2003. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. <italic>The Journal of experimental medicine</italic> 198:1875-1886.</p>
<p>Erecińska, M., and F. Dagani. 1990. Relationships between the neuronal sodium/potassium pump and energy metabolism. Effects of K+, Na+, and adenosine triphosphate in isolated brain synaptosomes. <italic>J Gen Physiol</italic> 95:591-616.</p>
<p>Fathman, C.G., and N.B. Lineberry. 2007. Molecular mechanisms of CD4+ T-cell anergy. <italic>Nat Rev Immunol</italic> 7:599-609.</p>
<p>Gerkau, N.J., R. Lerchundi, J.S.E. Nelson, M. Lantermann, J. Meyer, J. Hirrlinger, and C.R. Rose. 2019. Relation between activity-induced intracellular sodium transients and ATP dynamics in mouse hippocampal neurons. <italic>The Journal of physiology</italic> 597:5687-5705.</p>
<p>Hurrell, B.P., D.G. Helou, E. Howard, J.D. Painter, P. Shafiei-Jahani, A.H. Sharpe, and O. Akbari. 2022. PD-L2 controls peripherally induced regulatory T cells by maintaining metabolic activity and Foxp3 stability. <italic>Nature communications</italic> 13:5118.</p>
<p>Jenkins, M.K., and R.H. Schwartz. 1987. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. <italic>The Journal of experimental medicine</italic> 165:302-319.</p>
<p>John, P., M.C. Pulanco, P.M. Galbo, Jr., Y. Wei, K.C. Ohaegbulam, D. Zheng, and X. Zang. 2022. The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy. <italic>Nature communications</italic> 13:2506.</p>
<p>Kahlfuss, S., U. Kaufmann, A.R. Concepcion, L. Noyer, D. Raphael, M. Vaeth, J. Yang, P. Pancholi, M. Maus, J. Muller, L. Kozhaya, A. Khodadadi-Jamayran, Z. Sun, P. Shaw, D. Unutmaz, P.B. Stathopulos, C. Feist, S.B. Cameron, S.E. Turvey, and S. Feske. 2020. STIM1-mediated calcium influx controls antifungal immunity and the metabolic function of nonpathogenic Th17 cells. <italic>EMBO molecular medicine</italic> 12:e11592.</p>
<p>Levin, M. 2021. Bioelectric signaling: Reprogrammable circuits underlying embryogenesis, regeneration, and cancer. <italic>Cell</italic> 184:1971-1989.</p>
<p>Nagy, E., G. Mocsar, V. Sebestyen, J. Volko, F. Papp, K. Toth, S. Damjanovich, G. Panyi, T.A. Waldmann, A. Bodnar, and G. Vamosi. 2018. Membrane Potential Distinctly Modulates Mobility and Signaling of IL-2 and IL-15 Receptors in T Cells. <italic>Biophys J</italic> 114:2473-2482.</p>
<p>Quill, H., and R.H. Schwartz. 1987. Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness. <italic>Journal of immunology (Baltimore, Md. : 1950)</italic> 138:3704-3712.</p>
<p>Schmitt, E.G., and C.B. Williams. 2013. Generation and function of induced regulatory T cells. <italic>Frontiers in immunology</italic> 4:152.</p>
<p>Sugiura, A., G. Andrejeva, K. Voss, D.R. Heintzman, X. Xu, M.Z. Madden, X. Ye, K.L. Beier, N.U. Chowdhury, M.M. Wolf, A.C. Young, D.L. Greenwood, A.E. Sewell, S.K. Shahi, S.N. Freedman, A.M. Cameron, P. Foerch, T. Bourne, J.C. Garcia-Canaveras, J. Karijolich, D.C. Newcomb, A.K. Mangalam, J.D. Rabinowitz, and J.C. Rathmell. 2022. MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function. <italic>Immunity</italic> 55:65-81.e69.</p>
<p>Vaeth, M., and S. Feske. 2018. Ion channelopathies of the immune system. <italic>Current opinion in immunology</italic> 52:39-50.</p>
<p>Vanasek, T.L., S.L. Nandiwada, M.K. Jenkins, and D.L. Mueller. 2006. CD25+Foxp3+ regulatory T cells facilitate CD4+ T cell clonal anergy induction during the recovery from lymphopenia. <italic>Journal of immunology (Baltimore, Md. :1950)</italic> 176:5880-5889.</p>
<p>Wang, Y., A. Tao, M. Vaeth, and S. Feske. 2020. Calcium regulation of T cell metabolism. <italic>Current opinion in physiology</italic> 17:207-223.</p>
<p>Yu, W., Z. Wang, X. Yu, Y. Zhao, Z. Xie, K. Zhang, Z. Chi, S. Chen, T. Xu, D. Jiang, X. Guo, M. Li, J. Zhang, H. Fang, D. Yang, Y. Guo, X. Yang, X. Zhang, Y. Wu, W. Yang, and D. Wang. 2022. Kir2.1-mediated membrane potential promotes nutrient acquisition and inflammation through regulation of nutrient transporters. <italic>Nature communications</italic> 13:3544.</p>
<p>Zheng, S.G., J.D. Gray, K. Ohtsuka, S. Yamagiwa, and D.A. Horwitz. 2002. Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors. <italic>Journal of immunology (Baltimore, Md. : 1950)</italic> 169:4183-4189.</p>
</body>
</sub-article>
</article>